Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication.
Kolh, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biochimie et physiologie générales, humaines et pathologiques
Editor's Choice -- European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication.
Date de publication/diffusion :
janvier 2024
Titre du périodique :
European Journal of Vascular and Endovascular Surgery
Conte, M.S., Bradbury, A.W., Kolh, P., White, J.V., Dick, F., Fitridge, R., et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg 58 (2019), S1–S109.
Brouwers, M.C., Kerkvliet, K., Spithoff, K., AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ, 352, 2016, i1152.
Antoniou, G.A., Bastos Goncalves, F., Bjorck, M., Chakfe, N., Coscas, R., Dias, N.V., et al. Editor's Choice - European Society for Vascular Surgery Clinical Practice Guideline Development Scheme: An Overview of Evidence Quality Assessment Methods, Evidence to Decision Frameworks, and Reporting Standards in Guideline Development. Eur J Vasc Endovasc Surg 63 (2022), 791–799.
Arndt, H., Nordanstig, J., Bertges, D.J., Budtz-Lilly, J., Venermo, M., Espada, C.L., et al. A Delphi Consensus on patient reported outcomes for registries and trials including patients with intermittent claudication: recommendations and reporting standard. Eur J Vasc Endovasc Surg 64 (2022), 526–533.
Koeckerling, D., Raguindin, P.F., Kastrati, L., Bernhard, S., Barker, J., Quiroga Centeno, A.C., et al. Endovascular revascularization strategies for aortoiliac and femoropopliteal artery disease: a meta-analysis. Eur Heart J 44 (2023), 935–950.
Aboyans, V., Ricco, J.B., Bartelink, M.E.L., Bjorck, M., Brodmann, M., Cohnert, T., et al. Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 55 (2018), 305–368.
Bjorck, M., Earnshaw, J.J., Acosta, S., Bastos Goncalves, F., Cochennec, F., Debus, E.S., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia. Eur J Vasc Endovasc Surg 59 (2020), 173–218.
Conte, M.S., Data, guidelines, and practice of revascularization for claudication. J Vasc Surg 66 (2017), 911–915.
Jung, K.S., Heo, S.H., Woo, S.Y., Park, Y.J., Kim, D.I., Kim, Y.W., Factors associated with long-term graft patency after lower extremity arterial bypasses. Ann Surg Treat Res 100 (2021), 175–185.
Martinez, R.A., Shnayder, M., Parreco, J., Gaffney, L., Eby, M., Cortolillo, N., et al. Nationally representative readmission factors in patients with claudication and critical limb ischemia. Ann Vasc Surg 52 (2018), 96–107.
Bodewes, T.C., Soden, P.A., Ultee, K.H., Zettervall, S.L., Pothof, A.B., Deery, S.E., et al. Risk factors for 30-day unplanned readmission following infrainguinal endovascular interventions. J Vasc Surg 65 (2017), 484–494.
Smith, S.L., Matthews, E.O., Moxon, J.V., Golledge, J., A systematic review and meta-analysis of risk factors for and incidence of 30-day readmission after revascularization for peripheral artery disease. J Vasc Surg 70 (2019), 996–1006.
Kuy, S., Dua, A., Desai, S., Dua, A., Patel, B., Tondravi, N., et al. Surgical site infections after lower extremity revascularization procedures involving groin incisions. Ann Vasc Surg 28 (2014), 53–58.
Groin wound Infection after Vascular Exposure Study Group. Groin wound Infection after Vascular Exposure (GIVE) multicentre cohort study. Int Wound J 18 (2021), 164–175.
Gwilym, B.L., Ambler, G.K., Saratzis, A., Bosanquet, D.C., Groin wound Infection after Vascular Exposure Study Group. Groin wound Infection after Vascular Exposure (GIVE) risk prediction models: development, internal validation, and comparison with existing risk prediction models identified in a systematic literature review. Eur J Vasc Endovasc Surg 62 (2021), 258–266.
Kumakura, H., Kanai, H., Hojo, Y., Iwasaki, T., Ichikawa, S., Long-term survival and fate of the leg in de novo intermittent claudication. Eur Heart J Qual Care Clin Outcomes 3 (2017), 208–215.
Ochoa Chaar, C.I., Gholitabar, N., DeTrani, M., Jorshery, S.D., Zhuo, H., Zhang, Y., et al. The Reintervention Index: a new outcome measure for comparative effectiveness of lower extremity revascularization. Ann Vasc Surg 69 (2020), 52–61.
Golledge, J., Moxon, J.V., Rowbotham, S., Pinchbeck, J., Yip, L., Velu, R., et al. Risk of major amputation in patients with intermittent claudication undergoing early revascularization. Br J Surg 105 (2018), 699–708.
Djerf, H., Hellman, J., Baubeta Fridh, E., Andersson, M., Nordanstig, J., Falkenberg, M., Low risk of procedure related major amputation following revascularisation for intermittent claudication: a population based study. Eur J Vasc Endovasc Surg 59 (2020), 817–822.
Kim, T.I., Kiwan, G., Mohamedali, A., Zhang, Y., Dardik, A., Guzman, R.J., et al. Multiple reinterventions for claudication are associated with progression to chronic limb-threatening ischemia. Ann Vasc Surg 72 (2021), 166–174.
Madabhushi, V., Davenport, D., Jones, S., Khoudoud, S.A., Orr, N., Minion, D., et al. Revascularization of intermittent claudicants leads to more chronic limb-threatening ischemia and higher amputation rates. J Vasc Surg 74 (2021), 771–779.
Ubbink, D.T., Koelemay, M.J.W., Shared decision making in vascular surgery. Why would you?. Eur J Vasc Endovasc Surg 56 (2018), 749–750.
Bath, J., Lawrence, P.F., Neal, D., Zhao, Y., Smith, J.B., Beck, A.W., et al. Endovascular interventions for claudication do not meet minimum standards for the Society for Vascular Surgery efficacy guidelines. J Vasc Surg 73 (2021), 1693–1700.
Feinglass, J., McCarthy, W.J., Slavensky, R., Manheim, L.M., Martin, G.J., Effect of lower extremity blood pressure on physical functioning in patients who have intermittent claudication. The Chicago Claudication Outcomes Research Group. J Vasc Surg 24 (1996), 503–511.
McDermott, M.M., Greenland, P., Liu, K., Guralnik, J.M., Celic, L., Criqui, M.H., et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 136 (2002), 873–883.
McDermott, M.M., Ferrucci, L., Guralnik, J.M., Dyer, A.R., Liu, K., Pearce, W.H., et al. The ankle-brachial index is associated with the magnitude of impaired walking endurance among men and women with peripheral arterial disease. Vasc Med 15 (2010), 251–257.
Anderson, J.D., Epstein, F.H., Meyer, C.H., Hagspiel, K.D., Wang, H., Berr, S.S., et al. Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism. J Am Coll Cardiol 54 (2009), 628–635.
Mullins, C.H., Novak, Z., Axley, J.C., Sutzko, D.C., Spangler, E.L., Pearce, B.J., et al. Prevalence and outcomes of endovascular infrapopliteal interventions for intermittent claudication. Ann Vasc Surg 70 (2021), 79–86.
Fashandi, A.Z., Mehaffey, J.H., Hawkins, R.B., Kron, I.L., Upchurch, G.R. Jr., Robinson, W.P., Major adverse limb events and major adverse cardiac events after contemporary lower extremity bypass and infrainguinal endovascular intervention in patients with claudication. J Vasc Surg 68 (2018), 1817–1823.
Zhou, Y., Zhang, Z., Lin, S., Xiao, J., Ai, W., Wang, J., et al. Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions: a network meta-analysis of randomized controlled trials. J Endovasc Ther 27 (2020), 42–59.
Soga, Y., Yokoi, H., Urakawa, T., Tosaka, A., Iwabuchi, M., Nobuyoshi, M., Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease. Circ J 74 (2010), 1689–1695.
Levin, S.R., Farber, A., Osborne, N.H., Beck, A.W., McFarland, G.E., Rybin, D., et al. Tibial bypass in patients with intermittent claudication is associated with poor outcomes. J Vasc Surg 73 (2021), 564–571.
Mohler, E.R. 3rd, Hiatt, W.R., Creager, M.A., Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003), 1481–1486.
Mondillo, S., Ballo, P., Barbati, R., Guerrini, F., Ammaturo, T., Agricola, E., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003), 359–364.
Aung, P.P., Maxwell, H.G., Jepson, R.G., Price, J.F., Leng, G.C., Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev, 2007, 2007, CD000123.
Pastori, D., Farcomeni, A., Milanese, A., Del Sole, F., Menichelli, D., Hiatt, W.R., et al. Statins and major adverse limb events in patients with peripheral artery disease: a systematic review and meta-analysis. Thromb Haemost 120 (2020), 866–875.
Twine, C.P., Kakkos, S.K., Aboyans, V., Baumgartner, I., Behrendt, C.A., Bellmunt-Montoya, S., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg 65 (2023), 627–689.
Behrendt, C.A., Kreutzburg, T., Nordanstig, J., Twine, C.P., Marschall, U., Kakkos, S., et al. The OAC(3)-PAD Risk Score predicts major bleeding events one year after hospitalisation for peripheral artery disease. Eur J Vasc Endovasc Surg 63 (2022), 503–510.
Peters, F., Behrendt, C.A., External validation of the OAC3-PAD Risk Score to predict major bleeding events using the prospective GermanVasc Cohort Study. Eur J Vasc Endovasc Surg 64 (2022), 429–430.
Lareyre, F., Behrendt, C.A., Pradier, C., Settembre, N., Chaudhuri, A., Fabre, R., et al. Nationwide study in France to predict one year major bleeding and validate the OAC3-PAD score in patients undergoing revascularisation for lower extremity arterial disease. Eur J Vasc Endovasc Surg 66 (2023), 213–219.
Twine, C.P., Kakkos, S.K., Aboyans, V., Baumgartner, I., Behrendt, C.A., Bellmunt-Montoya, S., et al. European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. Eur J Vasc Endovasc Surg 65 (2023), 627–689.
Ponce, O.J., Larrea-Mantilla, L., Hemmingsen, B., Serrano, V., Rodriguez-Gutierrez, R., Spencer-Bonilla, G., et al. Lipid-lowering agents in older individuals: a systematic review and meta-analysis of randomized clinical trials. J Clin Endocrinol Metab 104 (2019), 1585–1594.
Angelidi, A.M., Stambolliu, E., Adamopoulou, K.I., Kousoulis, A.A., Is atorvastatin associated with new onset diabetes or deterioration of glycemic control? Systematic review using data from 1.9 million patients. Int J Endocrinol, 2018, 2018, 8380192.
Neves, J.S., Newman, C., Bostrom, J.A., Buysschaert, M., Newman, J.D., Medina, J.L., et al. Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes. Diabetes Res Clin Pract, 190, 2022, 109980.
Iwere, R.B., Hewitt, J., Myopathy in older people receiving statin therapy: a systematic review and meta-analysis. Br J Clin Pharmacol 80 (2015), 363–371.
McClure, D.L., Valuck, R.J., Glanz, M., Hokanson, J.E., Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 16 (2007), 132–143.
Kashani, A., Phillips, C.O., Foody, J.M., Wang, Y., Mangalmurti, S., Ko, D.T., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114 (2006), 2788–2797.
Rosenbaum, D., Dallongeville, J., Sabouret, P., Bruckert, E., Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis 23 (2013), 871–875.
Bytyci, I., Penson, P.E., Mikhailidis, D.P., Wong, N.D., Hernandez, A.V., Sahebkar, A., et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 43 (2022), 3213–3223.
Cholesterol Treatment Trialists Collaborators. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 400 (2022), 832–845.
Gupta, A., Thompson, D., Whitehouse, A., Collier, T., Dahlof, B., Poulter, N., et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. Lancet 389 (2017), 2473–2481.
Wood, F.A., Howard, J.P., Finegold, J.A., Nowbar, A.N., Thompson, D.M., Arnold, A.D., et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. N Engl J Med 383 (2020), 2182–2184.
Giral, P., Neumann, A., Weill, A., Coste, J., Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J 40 (2019), 3516–3525.
Staffa, J.A., Chang, J., Green, L., Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346 (2002), 539–540.
Golledge, J., Ward, N.C., Watts, G.F., Lipid management in people with peripheral artery disease. Curr Opin Lipidol 30 (2019), 470–476.
Frank, U., Nikol, S., Belch, J., Boc, V., Brodmann, M., Carpentier, P.H., et al. ESVM Guideline on peripheral arterial disease. Vasa 48 (2019), 1–79.
Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., Bakal, C.W., Creager, M.A., Halperin, J.L., et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic). Circulation 113 (2006), e463–e654.
Gordon, T., Kannel, W.B., Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. JAMA 221 (1972), 661–666.
Hardman, R.L., Jazaeri, O., Yi, J., Smith, M., Gupta, R., Overview of classification systems in peripheral artery disease. Semin Intervent Radiol 31 (2014), 378–388.
Xu, D., Zou, L., Xing, Y., Hou, L., Wei, Y., Zhang, J., et al. Diagnostic value of ankle-brachial index in peripheral arterial disease: a meta-analysis. Can J Cardiol 29 (2013), 492–498.
Criqui, M.H., Aboyans, V., Epidemiology of peripheral artery disease. Circ Res 116 (2015), 1509–1526.
Sartipy, F., Lundin, F., Wahlberg, E., Sigvant, B., Cardiovascular long-term outcome and prophylactic treatment patterns in peripheral arterial disease in a population-based cohort. Eur Heart J Qual Care Clin Outcomes 5 (2019), 310–320.
Aboyans, V., Criqui, M.H., Abraham, P., Allison, M.A., Creager, M.A., Diehm, C., et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation 126 (2012), 2890–2909.
Song, P., Rudan, D., Zhu, Y., Fowkes, F.J.I., Rahimi, K., Fowkes, F.G.R., et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health 7 (2019), e1020–e1030.
Fowkes, F.G., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J.O., McDermott, M.M., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382 (2013), 1329–1340.
Chen, Q., Li, L., Chen, Q., Lin, X., Li, Y., Huang, K., et al. Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review. BMC Cardiovasc Disord, 19, 2019, 17.
Hirsch, A.T., Criqui, M.H., Treat-Jacobson, D., Regensteiner, J.G., Creager, M.A., Olin, J.W., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286 (2001), 1317–1324.
Sigvant, B., Wiberg-Hedman, K., Bergqvist, D., Rolandsson, O., Andersson, B., Persson, E., et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg 45 (2007), 1185–1191.
Cimminiello, C., Borghi, C., Kownator, S., Wautrecht, J.C., Carvounis, C.P., Kranendonk, S.E., et al. Prevalence of peripheral arterial disease in patients at non-high cardiovascular risk. Rationale and design of the PANDORA study. BMC Cardiovasc Disord, 10, 2010, 35.
Cimminiello, C., Kownator, S., Wautrecht, J.C., Carvounis, C.P., Kranendonk, S.E., Kindler, B., et al. The PANDORA study: peripheral arterial disease in patients with non-high cardiovascular risk. Intern Emerg Med 6 (2011), 509–519.
Fowkes, F.G., Housley, E., Cawood, E.H., Macintyre, C.C., Ruckley, C.V., Prescott, R.J., Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 20 (1991), 384–392.
Søgaard, M., Nordanstig, J., Eldrup, N., Behrendt, C.A., A thought-provoking statement regarding the treatment of patients with peripheral arterial disease. Vasa 52 (2023), 77–80.
Kroger, K., Bock, E., Hohenberger, T., Moysidis, T., Santosa, F., Pfeifer, M., et al. ABI derived from the highest and lowest ankle pressure. What is the difference?. Int Angiol 29 (2010), 482–488.
Allison, M.A., Aboyans, V., Granston, T., McDermott, M.M., Kamineni, A., Ni, H., et al. The relevance of different methods of calculating the ankle-brachial index: the multi-ethnic study of atherosclerosis. Am J Epidemiol 171 (2010), 368–376.
Velescu, A., Clara, A., Penafiel, J., Grau, M., Degano, I.R., Marti, R., et al. Peripheral arterial disease incidence and associated risk factors in a Mediterranean population-based cohort. The REGICOR Study. Eur J Vasc Endovasc Surg 51 (2016), 696–705.
Weiss, N.S., McClelland, R., Criqui, M.H., Wassel, C.L., Kronmal, R., Incidence and predictors of clinical peripheral artery disease in asymptomatic persons with a low ankle-brachial index. J Med Screen 25 (2018), 218–222.
Lupilov, A., Krause, D., Klaassen-Mielke, R., Trampisch, H.J., Rudolf, H., Effects of three different methods defining onset of peripheral artery disease on the assessments of incidence and important predictors - results from the German Epidemiological Trial on Ankle Brachial Index (getABI). Vasc Health Risk Manag 17 (2021), 421–429.
Kreutzburg, T., Peters, F., Riess, H.C., Hischke, S., Marschall, U., Kriston, L., et al. Editor's Choice - Comorbidity patterns among patients with peripheral arterial occlusive disease in Germany: a trend analysis of health insurance claims data. Eur J Vasc Endovasc Surg 59 (2020), 59–66.
Behrendt, C.A., Thomalla, G., Rimmele, D.L., Petersen, E.L., Twerenbold, R., Debus, E.S., et al. Editor's Choice - Prevalence of peripheral arterial disease, abdominal aortic aneurysm, and risk factors in the Hamburg City Health Study: a cross sectional analysis. Eur J Vasc Endovasc Surg 65 (2023), 590–598.
Rose, G.A., The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27 (1962), 645–658.
Criqui, M.H., Denenberg, J.O., Bird, C.E., Fronek, A., Klauber, M.R., Langer, R.D., The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med 1 (1996), 65–71.
Jensen, S.A., Vatten, L.J., Romundstad, P.R., Myhre, H.O., The prevalence of intermittent claudication. Sex-related differences have been eliminated. Eur J Vasc Endovasc Surg 25 (2003), 209–212.
Diehm, C., Schuster, A., Allenberg, J.R., Darius, H., Haberl, R., Lange, S., et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. Atherosclerosis 172 (2004), 95–105.
Krishna, M., Oommen, A.M., Paul, G.J.S., Abraham, V.J., George, K., Prevalence of intermittent claudication in rural and urban Vellore, Tamil Nadu, India: a population-based study. Int Surg J, 5, 2018, 3.
Smith, F.B., Lee, A.J., Price, J.F., van Wijk, M.C., Fowkes, F.G., Changes in ankle brachial index in symptomatic and asymptomatic subjects in the general population. J Vasc Surg 38 (2003), 1323–1330.
Sigvant, B., Lundin, F., Wahlberg, E., The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease. Eur J Vasc Endovasc Surg 51 (2016), 395–403.
Mohler, E.R. 3rd, Bundens, W., Denenberg, J., Medenilla, E., Hiatt, W.R., Criqui, M.H., Progression of asymptomatic peripheral artery disease over 1 year. Vasc Med 17 (2012), 10–16.
Gao, X., Tong, Z., Wu, Y., Guo, L., Gu, Y., Dardik, A., Similarities and differences in peripheral artery disease between China and Western countries. J Vasc Surg 74 (2021), 1417–14124 e1.
Hooi, J.D., Kester, A.D., Stoffers, H.E., Overdijk, M.M., van Ree, J.W., Knottnerus, J.A., Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 153 (2001), 666–672.
Hooi, J.D., Kester, A.D., Stoffers, H.E., Rinkens, P.E., Knottnerus, J.A., van Ree, J.W., Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 57 (2004), 294–300.
Leng, G.C., Fowkes, F.G., Lee, A.J., Dunbar, J., Housley, E., Ruckley, C.V., Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 313 (1996), 1440–1444.
Ankle Brachial Index Collaboration Fowkes, F.G., Murray, G.D., Butcher, I., Heald, C.L., Lee, R.J., et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300 (2008), 197–208.
Sartipy, F., Sigvant, B., Lundin, F., Wahlberg, E., Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg 55 (2018), 529–536.
Hajibandeh, S., Hajibandeh, S., Shah, S., Child, E., Antoniou, G.A., Torella, F., Prognostic significance of ankle brachial pressure index: a systematic review and meta-analysis. Vascular 25 (2017), 208–224.
Criqui, M.H., Langer, R.D., Fronek, A., Feigelson, H.S., Klauber, M.R., McCann, T.J., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992), 381–386.
Aquino, R., Johnnides, C., Makaroun, M., Whittle, J.C., Muluk, V.S., Kelley, M.E., et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg 34 (2001), 962–970.
Baubeta Fridh, E., Andersson, M., Thuresson, M., Sigvant, B., Kragsterman, B., Johansson, S., et al. Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population based study. Eur J Vasc Endovasc Surg 54 (2017), 480–486.
Kreutzburg, T., Peters, F., Kuchenbecker, J., Marschall, U., Lee, R., Kriston, L., et al. Editor's Choice - The GermanVasc Score: A Pragmatic Risk Score Predicts Five Year Amputation Free Survival in Patients with Peripheral Arterial Occlusive Disease. Eur J Vasc Endovasc Surg 61 (2021), 248–256.
Droz-Perroteau, C., Blin, P., Dureau-Pournin, C., Thomas, D., Danchin, N., Tricoire, J., et al. Six-year survival study after myocardial infarction: the EOLE prospective cohort study. Long-term survival after MI. Therapie 74 (2019), 459–468.
Goodall, R., Salciccioli, J.D., Davies, A.H., Marshall, D., Shalhoub, J., Trends in peripheral arterial disease incidence and mortality in EU15+ countries 1990–2017. Eur J Prev Cardiol 28 (2021), 1201–1213.
Malyar, N., Freisinger, E., Reinecke, H., [Peripheral Arterial Disease - Trends in Morbidity and Mortality]. Dtsch Med Wochenschr 143 (2018), 766–770.
Brand, A.R., Houben, E., Bezemer, I.D., Visseren, F.L.J., Bots, M.L., Herings, R.M., et al. Platelet aggregation inhibitor prescription for newly diagnosed peripheral arterial disease in the Netherlands: a cohort study. BMJ Open, 11, 2021, e041715.
Welten, G.M., Schouten, O., Hoeks, S.E., Chonchol, M., Vidakovic, R., van Domburg, R.T., et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. J Am Coll Cardiol 51 (2008), 1588–1596.
Savji, N., Rockman, C.B., Skolnick, A.H., Guo, Y., Adelman, M.A., Riles, T., et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 61 (2013), 1736–1743.
Committee Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996), 1329–1339.
Aboyans, V., Desormais, I., Magne, J., Morange, G., Mohty, D., Lacroix, P., Renal artery stenosis in patients with peripheral artery disease: prevalence, risk factors and long-term prognosis. Eur J Vasc Endovasc Surg 53 (2017), 380–385.
Ahmed, B., Al-Khaffaf, H., Prevalence of significant asymptomatic carotid artery disease in patients with peripheral vascular disease: a meta-analysis. Eur J Vasc Endovasc Surg 37 (2009), 262–271.
Durand, D.J., Perler, B.A., Roseborough, G.S., Grega, M.A., Borowicz, L.M. Jr., Baumgartner, W.A., et al. Mandatory versus selective preoperative carotid screening: a retrospective analysis. Ann Thorac Surg 78 (2004), 159–166.
Fowkes, F.G., Low, L.P., Tuta, S., Kozak, J., AGATHA Investigators. Ankle-brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J 27 (2006), 1861–1867.
Mukherjee, D., Eagle, K.A., Kline-Rogers, E., Feldman, L.J., Juliard, J.M., Agnelli, G., et al. Impact of prior peripheral arterial disease and stroke on outcomes of acute coronary syndromes and effect of evidence-based therapies (from the Global Registry of Acute Coronary Events). Am J Cardiol 100 (2007), 1–6.
Naylor, A.R., Mehta, Z., Rothwell, P.M., Bell, P.R., Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. Eur J Vasc Endovasc Surg 23 (2002), 283–294.
Steinvil, A., Sadeh, B., Arbel, Y., Justo, D., Belei, A., Borenstein, N., et al. Prevalence and predictors of concomitant carotid and coronary artery atherosclerotic disease. J Am Coll Cardiol 57 (2011), 779–783.
Subherwal, S., Bhatt, D.L., Li, S., Wang, T.Y., Thomas, L., Alexander, K.P., et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes 5 (2012), 541–549.
Kim, E.K., Song, P.S., Yang, J.H., Song, Y.B., Hahn, J.Y., Choi, J.H., et al. Peripheral artery disease in Korean patients undergoing percutaneous coronary intervention: prevalence and association with coronary artery disease severity. J Korean Med Sci 28 (2013), 87–92.
Imori, Y., Akasaka, T., Ochiai, T., Oyama, K., Tobita, K., Shishido, K., et al. Co-existence of carotid artery disease, renal artery stenosis, and lower extremity peripheral arterial disease in patients with coronary artery disease. Am J Cardiol 113 (2014), 30–35.
Saw, J., Bhatt, D.L., Moliterno, D.J., Brener, S.J., Steinhubl, S.R., Lincoff, A.M., et al. The influence of peripheral arterial disease on outcomes: a pooled analysis of mortality in eight large randomized percutaneous coronary intervention trials. J Am Coll Cardiol 48 (2006), 1567–1572.
Hussein, A.A., Uno, K., Wolski, K., Kapadia, S., Schoenhagen, P., Tuzcu, E.M., et al. Peripheral arterial disease and progression of coronary atherosclerosis. J Am Coll Cardiol 57 (2011), 1220–1225.
Eagle, K.A., Rihal, C.S., Foster, E.D., Mickel, M.C., Gersh, B.J., Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. The Coronary Artery Surgery Study (CASS) Investigators. J Am Coll Cardiol 23 (1994), 1091–1095.
Grenon, S.M., Vittinghoff, E., Owens, C.D., Conte, M.S., Whooley, M., Cohen, B.E., Peripheral artery disease and risk of cardiovascular events in patients with coronary artery disease: insights from the Heart and Soul Study. Vasc Med 18 (2013), 176–184.
Inglis, S.C., Bebchuk, J., Al-Suhaim, S.A., Case, J., Pfeffer, M.A., Solomon, S.D., et al. Peripheral artery disease and outcomes after myocardial infarction: an individual-patient meta-analysis of 28,771 patients in CAPRICORN, EPEHESUS, OPTIMAAL and VALIANT. Int J Cardiol 168 (2013), 1094–1101.
Aboyans, V., Lacroix, P., Postil, A., Guilloux, J., Rolle, F., Cornu, E., et al. Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 46 (2005), 815–820.
Rihal, C.S., Sutton-Tyrrell, K., Guo, P., Keller, N.M., Jandova, R., Sellers, M.A., et al. Increased incidence of periprocedural complications among patients with peripheral vascular disease undergoing myocardial revascularization in the bypass angioplasty revascularization investigation. Circulation 100 (1999), 171–177.
Collet, J.P., Cayla, G., Ennezat, P.V., Leclercq, F., Cuisset, T., Elhadad, S., et al. Systematic detection of polyvascular disease combined with aggressive secondary prevention in patients presenting with severe coronary artery disease: the randomized AMERICA Study. Int J Cardiol 254 (2018), 36–42.
Aboyans, V., Lacroix, P., Guilloux, J., Rolle, F., Le Guyader, A., Cautres, M., et al. A predictive model for screening cerebrovascular disease in patient undergoing coronary artery bypass grafting. Interact Cardiovasc Thorac Surg 4 (2005), 90–95.
Anandasundaram, B., Lane, D.A., Apostolakis, S., Lip, G.Y., The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost 11 (2013), 975–987.
Goto, S., Bhatt, D.L., Rother, J., Alberts, M., Hill, M.D., Ikeda, Y., et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 156 (2008), 855–863.
Olesen, J.B., Lip, G.Y., Lane, D.A., Kober, L., Hansen, M.L., Karasoy, D., et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. Am J Med, 125, 2012, 826.
Naylor, R., Rantner, B., Ancetti, S., de Borst, G.J., De Carlo, M., Halliday, A., et al. Editor's Choice - European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on the Management of Atherosclerotic Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg 65 (2023), 7–111.
Amighi, J., Schlager, O., Haumer, M., Dick, P., Mlekusch, W., Loewe, C., et al. Renal artery stenosis predicts adverse cardiovascular and renal outcome in patients with peripheral artery disease. Eur J Clin Invest 39 (2009), 784–792.
Cooper, C.J., Murphy, T.P., Cutlip, D.E., Jamerson, K., Henrich, W., Reid, D.M., et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 370 (2014), 13–22.
A.S.T.R.A.L. Investigators Wheatley, K., Ives, N., Gray, R., Kalra, P.A., Moss, J.G., et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med 361 (2009), 1953–1962.
Matsushita, K., Ballew, S.H., Coresh, J., Arima, H., Arnlov, J., Cirillo, M., et al. Measures of chronic kidney disease and risk of incident peripheral artery disease: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 5 (2017), 718–728.
Gardner, A.W., Montgomery, P.S., Afaq, A., Exercise performance in patients with peripheral arterial disease who have different types of exertional leg pain. J Vasc Surg 46 (2007), 79–86.
Sigvant, B., Lundin, F., Nilsson, B., Bergqvist, D., Wahlberg, E., Differences in presentation of symptoms between women and men with intermittent claudication. BMC Cardiovasc Disord, 11, 2011, 39.
McDermott, M.M., Mehta, S., Greenland, P., Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease. Arch Intern Med 159 (1999), 387–392.
Dormandy, J., Heeck, L., Vig, S., The fate of patients with critical leg ischemia. Semin Vasc Surg 12 (1999), 142–147.
Belch, J.J., Topol, E.J., Agnelli, G., Bertrand, M., Califf, R.M., Clement, D.L., et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med 163 (2003), 884–892.
McDermott, M.M., Ferrucci, L., Liu, K., Guralnik, J.M., Tian, L., Liao, Y., et al. Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc 58 (2010), 1256–1262.
Santoro, L., Flex, A., Nesci, A., Ferraro, P.M., De Matteis, G., Di Giorgio, A., et al. Association between peripheral arterial disease and cardiovascular risk factors: role of ultrasonography versus ankle-brachial index. Eur Rev Med Pharmacol Sci 22 (2018), 3160–3165.
Serhal, A., Koktzoglou, I., Aouad, P., Carr, J.C., Giri, S., Morcos, O., et al. Cardiovascular magnetic resonance imaging of aorto-iliac and ilio-femoral vascular calcifications using proton density-weighted in-phase stack of stars. J Cardiovasc Magn Reson, 20, 2018, 51.
Tummala, S., Scherbel, D., Clinical assessment of peripheral arterial disease in the office: what do the guidelines say?. Semin Intervent Radiol 35 (2018), 365–377.
McDermott, M.M., Greenland, P., Liu, K., Guralnik, J.M., Criqui, M.H., Dolan, N.C., et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 286 (2001), 1599–1606.
McDermott, M.M., Guralnik, J.M., Ferrucci, L., Tian, L., Liu, K., Liao, Y., et al. Asymptomatic peripheral arterial disease is associated with more adverse lower extremity characteristics than intermittent claudication. Circulation 117 (2008), 2484–2491.
Matsushita, K., Ballew, S.H., Sang, Y., Kalbaugh, C., Loehr, L.R., Hirsch, A.T., et al. Ankle-brachial index and physical function in older individuals: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 257 (2017), 208–215.
McDermott, M.M., Liu, K., Greenland, P., Guralnik, J.M., Criqui, M.H., Chan, C., et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 292 (2004), 453–461.
Andras, A., Ferket, B., Screening for peripheral arterial disease. Cochrane Database Syst Rev, 2014, CD010835.
Bendermacher, B.L., Teijink, J.A., Willigendael, E.M., Bartelink, M.L., Peters, R.J., de Bie, R.A., et al. A clinical prediction model for the presence of peripheral arterial disease–the benefit of screening individuals before initiation of measurement of the ankle-brachial index: an observational study. Vasc Med 12 (2007), 5–11.
Ramos, R., Baena-Diez, J.M., Quesada, M., Solanas, P., Subirana, I., Sala, J., et al. Derivation and validation of REASON: a risk score identifying candidates to screen for peripheral arterial disease using ankle brachial index. Atherosclerosis 214 (2011), 474–479.
Guirguis-Blake, J.M., Evans, C.V., Redmond, N., Lin, J.S., Screening for peripheral artery disease using the ankle-brachial index: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA 320 (2018), 184–196.
Lindholt, J.S., Sogaard, R., Population screening and intervention for vascular disease in Danish men (VIVA): a randomised controlled trial. Lancet 390 (2017), 2256–2265.
Sogaard, R., Lindholt, J.S., Cost-effectiveness of population-based vascular disease screening and intervention in men from the Viborg Vascular (VIVA) trial. Br J Surg 105 (2018), 1283–1293.
Lindholt, J.S., Sogaard, R., Rasmussen, L.M., Mejldal, A., Lambrechtsen, J., Steffensen, F.H., et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) Trial. N Engl J Med 387 (2022), 1385–1394.
Shah, S., Antoniou, G.A., Torella, F., Evidence-based analysis of peripheral arterial disease screening based on the WHO criteria. Int Angiol 36 (2017), 299–305.
Ferket, B.S., Spronk, S., Colkesen, E.B., Hunink, M.G., Systematic review of guidelines on peripheral artery disease screening. Am J Med 125 (2012), 198–208.
Abramson, B.L., Huckell, V., Anand, S., Forbes, T., Gupta, A., Harris, K., et al. Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary. Can J Cardiol 21 (2005), 997–1006.
Greenland, P., Alpert, J.S., Beller, G.A., Benjamin, E.J., Budoff, M.J., Fayad, Z.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 56 (2010), e50–e103.
Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 25 (2009), 567–579.
Grundy, S.M., Cleeman, J.I., Merz, C.N., Brewer, H.B. Jr., Clark, L.T., Hunninghake, D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004), 227–239.
Hirsch, A.T., Haskal, Z.J., Hertzer, N.R., Bakal, C.W., Creager, M.A., Halperin, J.L., et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 113 (2006), e463–e654.
National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002), 3143–3421.
Norgren, L., Hiatt, W.R., Dormandy, J.A., Nehler, M.R., Harris, K.A., Fowkes, F.G., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg 33:Suppl 1 (2007), S1–S75.
U.S. Preventive Services Task Force. Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151 (2009), 474–482.
Society for Vascular Surgery Lower Extremity Guidelines Writing Group Conte, M.S., Pomposelli, F.B., Clair, D.G., Geraghty, P.J., McKinsey, J.F., et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 61 (2015), 2S–41S.
Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., Barshes, N.R., Corriere, M.A., Drachman, D.E., et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 (2017), e726–e779.
Rooke, T.W., Hirsch, A.T., Misra, S., Sidawy, A.N., Beckman, J.A., Findeiss, L., et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 61 (2013), 1555–1570.
Alahdab, F., Wang, A.T., Elraiyah, T.A., Malgor, R.D., Rizvi, A.Z., Lane, M.A., et al. A systematic review for the screening for peripheral arterial disease in asymptomatic patients. J Vasc Surg 61 (2015), 42S–53S.
Weiss, D.J., Casale, G.P., Koutakis, P., Nella, A.A., Swanson, S.A., Zhu, Z., et al. Oxidative damage and myofiber degeneration in the gastrocnemius of patients with peripheral arterial disease. J Transl Med, 11, 2013, 230.
Gillani, S., Cao, J., Suzuki, T., Hak, D.J., The effect of ischemia reperfusion injury on skeletal muscle. Injury 43 (2012), 670–675.
Pipinos II, Judge, A.R., Selsby, J.T., Zhu, Z., Swanson, S.A., Nella, A.A., et al. The myopathy of peripheral arterial occlusive disease: Part 2. Oxidative stress, neuropathy, and shift in muscle fiber type. Vasc Endovascular Surg 42 (2008), 101–112.
Pipinos, I.I., Judge, A.R., Zhu, Z., Selsby, J.T., Swanson, S.A., Johanning, J.M., et al. Mitochondrial defects and oxidative damage in patients with peripheral arterial disease. Free Radic Biol Med 41 (2006), 262–269.
Woods, B.O., Clinical evaluation of the peripheral vasculature. Cardiol Clin 9 (1991), 413–427.
Arnold, J.F., Vascular assessment of the lower extremity with a chronic wound. Surg Clin North Am 100 (2020), 807–822.
Khan, N.A., Rahim, S.A., Anand, S.S., Simel, D.L., Panju, A., Does the clinical examination predict lower extremity peripheral arterial disease?. JAMA 295 (2006), 536–546.
Stoffers, H.E., Kester, A.D., Kaiser, V., Rinkens, P.E., Knottnerus, J.A., Diagnostic value of signs and symptoms associated with peripheral arterial occlusive disease seen in general practice: a multivariable approach. Med Decis Making 17 (1997), 61–70.
Nicholson, M.L., Byrne, R.L., Steele, G.A., Callum, K.G., Predictive value of bruits and Doppler pressure measurements in detecting lower limb arterial stenosis. Eur J Vasc Surg 7 (1993), 59–62.
Leng, G.C., Fowkes, F.G., The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 45 (1992), 1101–1109.
Norgren, L., Hiatt, W.R., Dormandy, J.A., Nehler, M.R., Harris, K.A., Fowkes, F.G., et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 45:Suppl S (2007), S5–S67.
Killewich, L.A., Martin, R., Cramer, M., Beach, K.W., Strandness, D.E. Jr., Pathophysiology of venous claudication. J Vasc Surg 1 (1984), 507–511.
Shabani Varaki, E., Gargiulo, G.D., Penkala, S., Breen, P.P., Peripheral vascular disease assessment in the lower limb: a review of current and emerging non-invasive diagnostic methods. Biomed Eng Online, 17, 2018, 61.
Alagha, M., Aherne, T.M., Hassanin, A., Zafar, A.S., Joyce, D.P., Mahmood, W., et al. Diagnostic performance of ankle-brachial pressure index in lower extremity arterial disease. Surg J (N Y) 7 (2021), e132–e137.
Casey, S., Lanting, S., Oldmeadow, C., Chuter, V., The reliability of the ankle brachial index: a systematic review. J Foot Ankle Res, 12, 2019, 39.
Normahani, P., Mustafa, C., Shalhoub, J., Davies, A.H., Norrie, J., Sounderajah, V., et al. A systematic review and meta-analysis of the diagnostic accuracy of point-of-care tests used to establish the presence of peripheral arterial disease in people with diabetes. J Vasc Surg 73 (2021), 1811–1820.
Xu, L., He, R., Hua, X., Zhao, J., Zhao, J., Zeng, H., et al. The value of ankle-branchial index screening for cardiovascular disease in type 2 diabetes. Diabetes Metab Res Rev, 35, 2019, e3076.
Wukich, D.K., Shen, W., Raspovic, K.M., Suder, N.C., Baril, D.T., Avgerinos, E., Noninvasive arterial testing in patients with diabetes: a guide for foot and ankle surgeons. Foot Ankle Int 36 (2015), 1391–1399.
Bhowmick, R., Bhattacharjee, P., Das, P., A clinical study of peripheral arterial disease in diabetes mellitus with reference to ankle brachial pressure index and doppler sonography. J Assoc Physicians India, 68, 2020, 51.
AbuRahma, A.F., Adams, E., AbuRahma, J., Mata, L.A., Dean, L.S., Caron, C., et al. Critical analysis and limitations of resting ankle-brachial index in the diagnosis of symptomatic peripheral arterial disease patients and the role of diabetes mellitus and chronic kidney disease. J Vasc Surg 71 (2020), 937–945.
Chuter, V.H., Searle, A., Barwick, A., Golledge, J., Leigh, L., Oldmeadow, C., et al. Estimating the diagnostic accuracy of the ankle-brachial pressure index for detecting peripheral arterial disease in people with diabetes: a systematic review and meta-analysis. Diabet Med, 38, 2021, e14379.
Brouwers, J., Willems, S.A., Goncalves, L.N., Hamming, J.F., Schepers, A., Reliability of bedside tests for diagnosing peripheral arterial disease in patients prone to medial arterial calcification: a systematic review. EClinicalMedicine, 50, 2022, 101532.
Bauersachs, R., Debus, S., Nehler, M., Huelsebeck, M., Balradj, J., Bowrin, K., et al. A targeted literature review of the disease burden in patients with symptomatic peripheral artery disease. Angiology 71 (2020), 303–314.
Resnick, H.E., Lindsay, R.S., McDermott, M.M., Devereux, R.B., Jones, K.L., Fabsitz, R.R., et al. Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation 109 (2004), 733–739.
Velescu, A., Clara, A., Marti, R., Ramos, R., Perez-Fernandez, S., Marcos, L., et al. Abnormally high ankle-brachial index is associated with all-cause and cardiovascular mortality: the REGICOR Study. Eur J Vasc Endovasc Surg 54 (2017), 370–377.
Golledge, J., Moxon, J.V., Rowbotham, S., Pinchbeck, J., Quigley, F., Jenkins, J., High ankle brachial index predicts high risk of cardiovascular events amongst people with peripheral artery disease. PLoS One, 15, 2020, e0242228.
Fowkes, F.G., Murray, G.D., Butcher, I., Folsom, A.R., Hirsch, A.T., Couper, D.J., et al. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J Prev Cardiol 21 (2014), 310–320.
Layden, J., Michaels, J., Bermingham, S., Higgins, B., Guideline Development Group. Diagnosis and management of lower limb peripheral arterial disease: summary of NICE guidance. BMJ, 345, 2012, e4947.
Conte, M.S., Pomposelli, F.B., Society for Vascular Surgery Practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. J Vasc Surg, 61, 2015, 1S.
Niazi, K., Khan, T.H., Easley, K.A., Diagnostic utility of the two methods of ankle brachial index in the detection of peripheral arterial disease of lower extremities. Catheter Cardiovasc Interv 68 (2006), 788–792.
Schroder, F., Diehm, N., Kareem, S., Ames, M., Pira, A., Zwettler, U., et al. A modified calculation of ankle-brachial pressure index is far more sensitive in the detection of peripheral arterial disease. J Vasc Surg 44 (2006), 531–536.
Espinola-Klein, C., Rupprecht, H.J., Bickel, C., Lackner, K., Savvidis, S., Messow, C.M., et al. Different calculations of ankle-brachial index and their impact on cardiovascular risk prediction. Circulation 118 (2008), 961–967.
Le Bivic, L., Magne, J., Guy-Moyat, B., Wojtyna, H., Lacroix, P., Blossier, J.D., et al. The intrinsic prognostic value of the ankle–brachial index is independent from its mode of calculation. Vasc Med 24 (2019), 23–31.
O'Hare, A.M., Katz, R., Shlipak, M.G., Cushman, M., Newman, A.B., Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 113 (2006), 388–393.
Donohue, C.M., Adler, J.V., Bolton, L.L., Peripheral arterial disease screening and diagnostic practice: a scoping review. Int Wound J 17 (2020), 32–44.
Weragoda, J., Seneviratne, R., Weerasinghe, M.C., Wijeyaratne, S.M., ABPI against colour duplex scan: a screening tool for detection of peripheral arterial disease in low resource setting approach to validation. Int J Vasc Med, 2016, 2016, 1390475.
Crawford, F., Welch, K., Andras, A., Chappell, F.M., Ankle brachial index for the diagnosis of lower limb peripheral arterial disease. Cochrane Database Syst Rev, 9, 2016, CD010680.
Klein, S., Hage, J.J., Measurement, calculation, and normal range of the ankle-arm index: a bibliometric analysis and recommendation for standardization. Ann Vasc Surg 20 (2006), 282–292.
Pereira Filho, A.J.G., Sartipy, F., Lundin, F., Wahlberg, E., Sigvant, B., Impact of ankle brachial index calculations on peripheral arterial disease prevalence and as a predictor of cardiovascular risk. Eur J Vasc Endovasc Surg 64 (2022), 217–224.
Chuter, V.H., Casey, S.L., Pre-measurement rest time affects magnitude and reliability of toe pressure measurements. Blood Press 24 (2015), 185–188.
Hoyer, C., Sandermann, J., Petersen, L.J., The toe-brachial index in the diagnosis of peripheral arterial disease. J Vasc Surg 58 (2013), 231–238.
Tyrrell, M.R., Wolfe, J.H., Critical leg ischaemia: an appraisal of clinical definitions. Joint Vascular Research Group. Br J Surg 80 (1993), 177–180.
Mills, J.L. Sr., Conte, M.S., Armstrong, D.G., Pomposelli, F.B., Schanzer, A., Sidawy, A.N., et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 59 (2014), 220–234.
de Graaff, J.C., Ubbink, D.T., Legemate, D.A., de Haan, R.J., Jacobs, M.J., Interobserver and intraobserver reproducibility of peripheral blood and oxygen pressure measurements in the assessment of lower extremity arterial disease. J Vasc Surg 33 (2001), 1033–1040.
Herraiz-Adillo, A., Cavero-Redondo, I., Alvarez-Bueno, C., Pozuelo-Carrascosa, D.P., Solera-Martinez, M., The accuracy of toe brachial index and ankle brachial index in the diagnosis of lower limb peripheral arterial disease: a systematic review and meta-analysis. Atherosclerosis 315 (2020), 81–92.
Tehan, P.E., Santos, D., Chuter, V.H., A systematic review of the sensitivity and specificity of the toe-brachial index for detecting peripheral artery disease. Vasc Med 21 (2016), 382–389.
Laivuori, M., Hakovirta, H., Kauhanen, P., Sinisalo, J., Sund, R., Alback, A., et al. Toe pressure should be part of a vascular surgeon's first-line investigation in the assessment of lower extremity artery disease and cardiovascular risk of a patient. J Vasc Surg 73 (2021), 641–649.
Hoogeveen, E.K., Mackaay, A.J., Beks, P.J., Kostense, P.J., Dekker, J.M., Heine, R.J., et al. Evaluation of the one-minute exercise test to detect peripheral arterial disease. Eur J Clin Invest 38 (2008), 290–295.
Birkett, S.T., Harwood, A.E., Caldow, E., Ibeggazene, S., Ingle, L., Pymer, S., A systematic review of exercise testing in patients with intermittent claudication: A focus on test standardisation and reporting quality in randomised controlled trials of exercise interventions. PLoS One, 16, 2021, e0249277.
Nicolai, S.P., Viechtbauer, W., Kruidenier, L.M., Candel, M.J., Prins, M.H., Teijink, J.A., Reliability of treadmill testing in peripheral arterial disease: a meta-regression analysis. J Vasc Surg 50 (2009), 322–329.
Gardner, A.W., Skinner, J.S., Cantwell, B.W., Smith, L.K., Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc 23 (1991), 402–408.
McDermott, M.M., Guralnik, J.M., Criqui, M.H., Liu, K., Kibbe, M.R., Ferrucci, L., Six-minute walk is a better outcome measure than treadmill walking tests in therapeutic trials of patients with peripheral artery disease. Circulation 130 (2014), 61–68.
Singh, S.J., Morgan, M.D., Scott, S., Walters, D., Hardman, A.E., Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 47 (1992), 1019–1024.
McDermott, M.M., Guralnik, J.M., Tian, L., Zhao, L., Polonsky, T.S., Kibbe, M.R., et al. Comparing 6-minute walk versus treadmill walking distance as outcomes in randomized trials of peripheral artery disease. J Vasc Surg 71 (2020), 988–1001.
McDermott, M.M., Ades, P.A., Dyer, A., Guralnik, J.M., Kibbe, M., Criqui, M.H., Corridor-based functional performance measures correlate better with physical activity during daily life than treadmill measures in persons with peripheral arterial disease. J Vasc Surg 48 (2008), 1231–1237.
Nordanstig, J., Broeren, M., Hensater, M., Perlander, A., Osterberg, K., Jivegard, L., Six-minute walk test closely correlates to “real-life” outdoor walking capacity and quality of life in patients with intermittent claudication. J Vasc Surg 60 (2014), 404–409.
Sandberg, A., Cider, A., Jivegard, L., Nordanstig, J., Wittboldt, S., Back, M., Test-retest reliability, agreement, and minimal detectable change in the 6-minute walk test in patients with intermittent claudication. J Vasc Surg 71 (2020), 197–203.
Nordanstig, J., Wann-Hansson, C., Karlsson, J., Lundstrom, M., Pettersson, M., Morgan, M.B., Vascular Quality of Life Questionnaire-6 facilitates health-related quality of life assessment in peripheral arterial disease. J Vasc Surg 59 (2014), 700–707.
Collins, R., Cranny, G., Burch, J., Aguiar-Ibanez, R., Craig, D., Wright, K., et al. A systematic review of duplex ultrasound, magnetic resonance angiography and computed tomography angiography for the diagnosis and assessment of symptomatic, lower limb peripheral arterial disease. Health Technol Assess, 11, 2007 iii–iv, xi–xiii, 1–184.
Visser, K., Hunink, M.G., Peripheral arterial disease: gadolinium-enhanced MR angiography versus color-guided duplex US–a meta-analysis. Radiology 216 (2000), 67–77.
Jens, S., Koelemay, M.J., Reekers, J.A., Bipat, S., Diagnostic performance of computed tomography angiography and contrast-enhanced magnetic resonance angiography in patients with critical limb ischaemia and intermittent claudication: systematic review and meta-analysis. Eur Radiol 23 (2013), 3104–3114.
Met, R., Bipat, S., Legemate, D.A., Reekers, J.A., Koelemay, M.J., Diagnostic performance of computed tomography angiography in peripheral arterial disease: a systematic review and meta-analysis. JAMA 301 (2009), 415–424.
Sun, Z., Diagnostic accuracy of multislice CT angiography in peripheral arterial disease. J Vasc Interv Radiol 17 (2006), 1915–1921.
van der Molen, A.J., Reimer, P., Dekkers, I.A., Bongartz, G., Bellin, M.F., Bertolotto, M., et al. Post-contrast acute kidney injury - Part 1: Definition, clinical features, incidence, role of contrast medium and risk factors: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28 (2018), 2845–2855.
Nijssen, E.C., Rennenberg, R.J., Nelemans, P.J., Essers, B.A., Janssen, M.M., Vermeeren, M.A., et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 389 (2017), 1312–1322.
van der Molen, A.J., Reimer, P., Dekkers, I.A., Bongartz, G., Bellin, M.F., Bertolotto, M., et al. Post-contrast acute kidney injury. Part 2: risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: recommendations for updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 28 (2018), 2856–2869.
Menke, J., Larsen, J., Meta-analysis: accuracy of contrast-enhanced magnetic resonance angiography for assessing steno-occlusions in peripheral arterial disease. Ann Intern Med 153 (2010), 325–334.
Koelemay, M.J., Lijmer, J.G., Stoker, J., Legemate, D.A., Bossuyt, P.M., Magnetic resonance angiography for the evaluation of lower extremity arterial disease: a meta-analysis. JAMA 285 (2001), 1338–1345.
Nelemans, P.J., Leiner, T., de Vet, H.C., van Engelshoven, J.M., Peripheral arterial disease: meta-analysis of the diagnostic performance of MR angiography. Radiology 217 (2000), 105–114.
Glikson, M., Nielsen, J.C., Kronborg, M.B., Michowitz, Y., Auricchio, A., Barbash, I.M., et al. [2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)]. G Ital Cardiol (Rome) 23 (2022), e1–e94.
Kallen, A.J., Jhung, M.A., Cheng, S., Hess, T., Turabelidze, G., Abramova, L., et al. Gadolinium-containing magnetic resonance imaging contrast and nephrogenic systemic fibrosis: a case-control study. Am J Kidney Dis 51 (2008), 966–975.
Woolen, S.A., Shankar, P.R., Gagnier, J.J., MacEachern, M.P., Singer, L., Davenport, M.S., Risk of nephrogenic systemic fibrosis in patients with stage 4 or 5 chronic kidney disease receiving a Group II gadolinium-based contrast agent: a systematic review and meta-analysis. JAMA Intern Med 180 (2020), 223–230.
Cavallo, A.U., Koktzoglou, I., Edelman, R.R., Gilkeson, R., Mihai, G., Shin, T., et al. Noncontrast magnetic resonance angiography for the diagnosis of peripheral vascular disease. Circ Cardiovasc Imaging, 12, 2019, e008844.
Takahashi, M., Koga, Y., Bussaka, H., Miyawaki, M., The value of digital subtraction angiography in peripheral vascular diseases. Br J Radiol 57 (1984), 123–132.
Blakeman, B.M., Littooy, F.N., Baker, W.H., Intra-arterial digital subtraction angiography as a method to study peripheral vascular disease. J Vasc Surg 4 (1986), 168–173.
Yong, O.Y., Ma, H.P., Gu, S.B., Zhou, Q.H., Zhang, S.L., Liu, P.Z., et al. Clinical application of DSA and evaluation of its methods: analysis of 160 cases and review of literature. Radiat Med 8 (1990), 71–78.
Ghumman, S.S., Weinerman, J., Khan, A., Cheema, M.S., Garcia, M., Levin, D., et al. Contrast induced-acute kidney injury following peripheral angiography with carbon dioxide versus iodinated contrast media: a meta-analysis and systematic review of current literature. Catheter Cardiovasc Interv 90 (2017), 437–448.
Verma, M., Pandey, N.N., Singh, V., Jagia, P., A meta-analysis of the diagnostic performance of quiescent-interval-single-shot magnetic resonance angiography in peripheral arterial disease. Eur Radiol 32 (2022), 2393–2403.
de Graaff, J.C., Ubbink, D.T., Legemate, D.A., Tijssen, J.G., Jacobs, M.J., Evaluation of toe pressure and transcutaneous oxygen measurements in management of chronic critical leg ischemia: a diagnostic randomized clinical trial. J Vasc Surg 38 (2003), 528–534.
Rother, U., Lang, W., Horch, R.E., Ludolph, I., Meyer, A., Gefeller, O., et al. Pilot assessment of the angiosome concept by intra-operative fluorescence angiography after tibial bypass surgery. Eur J Vasc Endovasc Surg 55 (2018), 215–221.
Rother, U., Krenz, K., Lang, W., Horch, R.E., Schmid, A., Heinz, M., et al. Immediate changes of angiosome perfusion during tibial angioplasty. J Vasc Surg 65 (2017), 422–430.
Castronuovo, J.J. Jr., Adera, H.M., Smiell, J.M., Price, R.M., Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg 26 (1997), 629–637.
Eiken, F.L., Pedersen, B.L., Baekgaard, N., Eiberg, J.P., Diagnostic methods for measurement of peripheral blood flow during exercise in patients with type 2 diabetes and peripheral artery disease: a systematic review. Int Angiol 38 (2019), 62–69.
Eslahpazir, B.A., Allemang, M.T., Lakin, R.O., Carman, T.L., Trivonovich, M.R., Wong, V.L., et al. Pulse volume recording does not enhance segmental pressure readings for peripheral arterial disease stratification. Ann Vasc Surg 28 (2014), 18–27.
Forsythe, R.O., Apelqvist, J., Boyko, E.J., Fitridge, R., Hong, J.P., Katsanos, K., et al. Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review. Diabetes Metab Res Rev, 36(Suppl 1), 2020, e3278.
Leenstra, B., Wijnand, J., Verhoeven, B., Koning, O., Teraa, M., Verhaar, M.C., et al. Applicability of transcutaneous oxygen tension measurement in the assessment of chronic limb-threatening ischemia. Angiology 71 (2020), 208–216.
Ma, K.F., Kleiss, S.F., Schuurmann, R.C.L., Bokkers, R.P.H., Unlu, C., De Vries, J.P.M., A systematic review of diagnostic techniques to determine tissue perfusion in patients with peripheral arterial disease. Expert Rev Med Devices 16 (2019), 697–710.
Forsythe, R.O., Apelqvist, J., Boyko, E.J., Fitridge, R., Hong, J.P., Katsanos, K., et al. Effectiveness of revascularisation of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. Diabetes Metab Res Rev, 36(Suppl 1), 2020, e3279.
Wermelink, B., Ma, K.F., Haalboom, M., El Moumni, M., de Vries, J.P.M., Geelkerken, R.H., A systematic review and critical appraisal of peri-procedural tissue perfusion techniques and their clinical value in patients with peripheral arterial disease. Eur J Vasc Endovasc Surg 62 (2021), 896–908.
Abraham, P., Colas-Ribas, C., Signolet, I., Ammi, M., Feuilloy, M., Picquet, J., et al. Transcutaneous exercise oximetry for patients with claudication - a retrospective review of approximately 5,000 consecutive tests over 15 years. Circ J 82 (2018), 1161–1167.
Forsythe, R.O., Apelqvist, J., Boyko, E.J., Fitridge, R., Hong, J.P., Katsanos, K., et al. Effectiveness of bedside investigations to diagnose peripheral artery disease among people with diabetes mellitus: a systematic review. Diabetes Metab Res Rev, 36(Suppl 1), 2020, e3277.
Torngren, K., Eriksson, S., Arvidsson, J., Falkenberg, M., Johnsson, A.A., Sjoberg, C., et al. A reperfusion BOLD-MRI tissue perfusion protocol reliably differentiate patients with peripheral arterial occlusive disease from healthy controls. J Clin Med, 10, 2021, 3643.
Behrendt, C.A., Bjorck, M., Schwaneberg, T., Debus, E.S., Cronenwett, J., Sigvant, B., et al. Editor's Choice - Recommendations for Registry Data Collection for Revascularisations of Acute Limb Ischaemia: A Delphi Consensus from the International Consortium of Vascular Registries. Eur J Vasc Endovasc Surg 57 (2019), 816–821.
Behrendt, C.A., Bertges, D., Eldrup, N., Beck, A.W., Mani, K., Venermo, M., et al. International Consortium of Vascular Registries Consensus Recommendations for Peripheral Revascularisation Registry Data Collection. Eur J Vasc Endovasc Surg 56 (2018), 217–237.
Fontaine, R., Kim, M., Kieny, R., [Surgical treatment of peripheral circulation disorders]. Helv Chir Acta 21 (1954), 499–533.
Committee, T.S., Jaff, M.R., White, C.J., Hiatt, W.R., Fowkes, G.R., Dormandy, J., et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: a supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Endovasc Ther 22 (2015), 663–677.
Fridh, E.B., Ludwigs, K., Svalkvist, A., Andersson, M., Nordanstig, J., Falkenberg, M., et al. Comparison of magnetic resonance angiography and digital subtraction angiography for the assessment of infrapopliteal arterial occlusive lesions, based on the TASC II Classification Criteria. Diagnostics (Basel), 10, 2020, 892.
Bollinger, A., Breddin, K., Hess, H., Heystraten, F.M., Kollath, J., Konttila, A., et al. Semiquantitative assessment of lower limb atherosclerosis from routine angiographic images. Atherosclerosis 38 (1981), 339–346.
Rondinelli, R.D., Genovese, E., Katz, R.T., Mayer, T.G., Mueller, K.L., Ranavaya, M.I., et al. AMA Guides to the Evaluation of Permanent Impairment. 6th Edition, 2008.
Conte, M.S., Bradbury, A.W., Kolh, P., White, J.V., Dick, F., Fitridge, R., et al. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg 58 (2019), S1–S109.
Nehler, M.R., McDermott, M.M., Treat-Jacobson, D., Chetter, I., Regensteiner, J.G., Functional outcomes and quality of life in peripheral arterial disease: current status. Vasc Med 8 (2003), 115–126.
Aber, A., Lumley, E., Phillips, P., Woods, H.B., Jones, G., Michaels, J., Themes that determine quality of life in patients with peripheral arterial disease: a systematic review. Patient 11 (2018), 489–502.
Higgins, J., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M., Welch, V., Cochrane Handbook for Systematic Reviews of Interventions. 2021, The Cochrane Collaboration Version 6.2.
Rymer, J.A., Mulder, H., Smolderen, K.G., Hiatt, W.R., Conte, M.S., Berger, J.S., et al. Association of Health Status Scores with cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: insights from the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial. J Am Heart Assoc, 9, 2020, e016573.
Mays, R.J., Casserly, I.P., Kohrt, W.M., Ho, P.M., Hiatt, W.R., Nehler, M.R., et al. Assessment of functional status and quality of life in claudication. J Vasc Surg 53 (2011), 1410–1421.
Poku, E., Duncan, R., Keetharuth, A., Essat, M., Phillips, P., Woods, H.B., et al. Patient-reported outcome measures in patients with peripheral arterial disease: a systematic review of psychometric properties. Health Qual Life Outcomes, 14, 2016, 161.
Conijn, A.P., Jens, S., Terwee, C.B., Breek, J.C., Koelemay, M.J., Assessing the quality of available patient reported outcome measures for intermittent claudication: a systematic review using the COSMIN checklist. Eur J Vasc Endovasc Surg 49 (2015), 316–334.
Kumlien, C., Nordanstig, J., Lundstrom, M., Pettersson, M., Validity and test retest reliability of the vascular quality of life Questionnaire-6: a short form of a disease-specific health-related quality of life instrument for patients with peripheral arterial disease. Health Qual Life Outcomes, 15, 2017, 187.
Larsen, A.S.F., Reiersen, A.T., Jacobsen, M.B., Klow, N.E., Nordanstig, J., Morgan, M., et al. Validation of the Vascular quality of life questionnaire - 6 for clinical use in patients with lower limb peripheral arterial disease. Health Qual Life Outcomes, 15, 2017, 184.
McDermott, M.M., Lloyd-Jones, D.M., The role of biomarkers and genetics in peripheral arterial disease. J Am Coll Cardiol 54 (2009), 1228–1237.
McDermott, M.M., Ferrucci, L., Guralnik, J.M., Tian, L., Green, D., Liu, K., et al. Elevated levels of inflammation, d-dimer, and homocysteine are associated with adverse calf muscle characteristics and reduced calf strength in peripheral arterial disease. J Am Coll Cardiol 50 (2007), 897–905.
Goodman, M.N., Interleukin-6 induces skeletal muscle protein breakdown in rats. Proc Soc Exp Biol Med 205 (1994), 182–185.
McDermott, M.M., Liu, K., Ferrucci, L., Tian, L., Guralnik, J.M., Green, D., et al. Circulating blood markers and functional impairment in peripheral arterial disease. J Am Geriatr Soc 56 (2008), 1504–1510.
Igari, K., Kudo, T., Toyofuku, T., Inoue, Y., Relationship of inflammatory biomarkers with severity of peripheral arterial disease. Int J Vasc Med, 2016, 2016, 6015701.
Signorelli, S.S., Anzaldi, M., Libra, M., Navolanic, P.M., Malaponte, G., Mangano, K., et al. Plasma levels of inflammatory biomarkers in peripheral arterial disease: results of a cohort study. Angiology 67 (2016), 870–874.
Signorelli, S.S., Mazzarino, M.C., Di Pino, L., Malaponte, G., Porto, C., Pennisi, G., et al. High circulating levels of cytokines (IL-6 and TNFalpha), adhesion molecules (VCAM-1 and ICAM-1) and selectins in patients with peripheral arterial disease at rest and after a treadmill test. Vasc Med 8 (2003), 15–19.
Engelberger, R.P., Limacher, A., Kucher, N., Baumann, F., Silbernagel, G., Benghozi, R., et al. Biological variation of established and novel biomarkers for atherosclerosis: results from a prospective, parallel-group cohort study. Clin Chim Acta 447 (2015), 16–22.
Pande, R.L., Brown, J., Buck, S., Redline, W., Doyle, J., Plutzky, J., et al. Association of monocyte tumor necrosis factor alpha expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease. J Vasc Surg 61 (2015), 155–161.
Valkova, M., Lazurova, I., Petrasova, D., Frankovicova, M., Dravecka, I., Humoral predictors of ankle-brachial index in patients with peripheral arterial disease and controls. Bratisl Lek Listy 119 (2018), 646–650.
Saenz-Pipaon, G., San Martin, P., Planell, N., Maillo, A., Ravassa, S., Vilas-Zornoza, A., et al. Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD). J Extracell Vesicles, 9, 2020, 1729646.
Signorelli, S.S., Anzaldi, M., Fiore, V., Simili, M., Puccia, G., Libra, M., et al. Patients with unrecognized peripheral arterial disease (PAD) assessed by ankle-brachial index (ABI) present a defined profile of proinflammatory markers compared to healthy subjects. Cytokine 59 (2012), 294–298.
Matsushita, K., Kwak, L., Yang, C., Pang, Y., Ballew, S.H., Sang, Y., et al. High-sensitivity cardiac troponin and natriuretic peptide with risk of lower-extremity peripheral artery disease: the Atherosclerosis Risk in Communities (ARIC) Study. Eur Heart J 39 (2018), 2412–2419.
Fatemi, S., Acosta, S., Gottsater, A., Melander, O., Engstrom, G., Dakhel, A., et al. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD. Biomarkers 24 (2019), 615–621.
Zhou, S.S., Jin, J.P., Wang, J.Q., Zhang, Z.G., Freedman, J.H., Zheng, Y., et al. miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges. Acta Pharmacol Sin 39 (2018), 1073–1084.
Schwartz, G.G., Steg, P.G., Szarek, M., Bittner, V.A., Diaz, R., Goodman, S.G., et al. Peripheral artery disease and venous thromboembolic events after acute coronary syndrome: role of lipoprotein(a) and modification by alirocumab: prespecified analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation 141 (2020), 1608–1617.
Golledge, J., Rowbotham, S., Velu, R., Quigley, F., Jenkins, J., Bourke, M., et al. Association of serum lipoprotein (a) with the requirement for a peripheral artery operation and the incidence of major adverse cardiovascular events in people with peripheral artery disease. J Am Heart Assoc, 9, 2020, e015355.
Kheirkhah, A., Lamina, C., Rantner, B., Kollerits, B., Stadler, M., Pohlhammer, J., et al. Elevated levels of serum PCSK9 in male patients with symptomatic peripheral artery disease: the CAVASIC study. Atherosclerosis 316 (2021), 41–47.
Yanaka, K., Akahori, H., Imanaka, T., Miki, K., Yoshihara, N., Kimura, T., et al. Relationship between lipoprotein(a) and angiographic severity of femoropopliteal lesions. J Atheroscler Thromb 28 (2021), 555–561.
Kremers, B., Wubbeke, L., Mees, B., Ten Cate, H., Spronk, H., Ten Cate-Hoek, A., Plasma biomarkers to predict cardiovascular outcome in patients with peripheral artery disease: a systematic review and meta-analysis. Arterioscler Thromb Vasc Biol 40 (2020), 2018–2032.
GBD 2015 Tobacco Collaborators. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015. Lancet 389 (2017), 1885–1906.
Young, J.C., Paul, N.J., Karatas, T.B., Kondrasov, S.A., McGinigle, K.L., Crowner, J.R., et al. Cigarette smoking intensity informs outcomes after open revascularization for peripheral artery disease. J Vasc Surg 70 (2019), 1973–1983 e5.
Kaschwich, M., Peters, F., Hischke, S., Riess, H.C., Gansel, M., Marschall, U., et al. Long-term incidence of cancer after index treatment for symptomatic peripheral arterial disease - a health insurance claims data analysis. Vasa 49 (2020), 493–499.
Armstrong, E.J., Wu, J., Singh, G.D., Dawson, D.L., Pevec, W.C., Amsterdam, E.A., et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg 60 (2014), 1565–1571.
Reitz, K.M., Althouse, A.D., Meyer, J., Arya, S., Goodney, P.P., Shireman, P.K., et al. Association of smoking with postprocedural complications following open and endovascular interventions for intermittent claudication. JAMA Cardiol 7 (2022), 45–54.
Patnode, C.D., Henderson, J.T., Thompson, J.H., Senger, C.A., Fortmann, S.P., Whitlock, E.P., Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. Preventive Services Task Force. Ann Intern Med 163 (2015), 608–621.
Hennrikus, D., Joseph, A.M., Lando, H.A., Duval, S., Ukestad, L., Kodl, M., et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol 56 (2010), 2105–2112.
US Preventive Services Task Force Krist, A.H., Davidson, K.W., Mangione, C.M., Barry, M.J., Cabana, M., et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force Recommendation Statement. JAMA 325 (2021), 265–279.
Barua, R.S., Rigotti, N.A., Benowitz, N.L., Cummings, K.M., Jazayeri, M.A., Morris, P.B., et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 72 (2018), 3332–3365.
Schnoll, R.A., Goelz, P.M., Veluz-Wilkins, A., Blazekovic, S., Powers, L., Leone, F.T., et al. Long-term nicotine replacement therapy: a randomized clinical trial. JAMA Intern Med 175 (2015), 504–511.
Wayne, G.F., Connolly, G., Henningfield, J., Brand differences of free-base nicotine delivery in cigarette smoke: the view of the tobacco industry documents. Tobacco Control 15 (2006), 189–198.
McNeill, A., Simonavicius, E., Brose, L., Taylor, E., East, K., Zuikova, E., et al. Nicotine vaping in England: an evidence update including health risks and perceptions, 2022. A report commissioned by the Office for Health Improvement and Disparities. 2022, Office for Health Improvement and Disparities 2022, London.
Peruzzi, M., Biondi-Zoccai, G., Carnevale, R., Cavarretta, E., Frati, G., Versaci, F., Vaping cardiovascular health risks: an updated umbrella review. Curr Emerg Hosp Med Rep 8 (2020), 103–109.
Wilson, N., Summers, J.A., Ait Ouakrim, D., Hoek, J., Edwards, R., Blakely, T., Improving on estimates of the potential relative harm to health from using modern ENDS (vaping) compared to tobacco smoking. BMC Public Health, 21, 2021, 2038.
Hartmann-Boyce, J., McRobbie, H., Butler, A.R., Lindson, N., Bullen, C., Begh, R., et al. Electronic cigarettes for smoking cessation. Cochrane Database Syst Rev, 9, 2021, CD010216.
Jorenby, D.E., Leischow, S.J., Nides, M.A., Rennard, S.I., Johnston, J.A., Hughes, A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340 (1999), 685–691.
Hays, J.T., Hurt, R.D., Rigotti, N.A., Niaura, R., Gonzales, D., Durcan, M.J., et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. Ann Intern Med 135 (2001), 423–433.
Suissa, K., Lariviere, J., Eisenberg, M.J., Eberg, M., Gore, G.C., Grad, R., et al. Efficacy and safety of smoking cessation interventions in patients with cardiovascular disease: a network meta-analysis of randomized controlled trials. Circ Cardiovasc Qual Outcomes, 10, 2017, e002458.
Ebbert, J.O., Hatsukami, D.K., Croghan, I.T., Schroeder, D.R., Allen, S.S., Hays, J.T., et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 311 (2014), 155–163.
Barua, R.S., Rigotti, N.A., Benowitz, N.L., Cummings, K.M., Jazayeri, M.-A., Morris, P.B., et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 72 (2018), 3332–3365.
Anthenelli, R.M., Benowitz, N.L., West, R., St Aubin, L., McRae, T., Lawrence, D., et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 387 (2016), 2507–2520.
Morgan, G.D., Noll, E.L., Orleans, C.T., Rimer, B.K., Amfoh, K., Bonney, G., Reaching midlife and older smokers: tailored interventions for routine medical care. Prev Med 25 (1996), 346–354.
Canga, N., De Irala, J., Vara, E., Duaso, M.J., Ferrer, A., Martinez-Gonzalez, M.A., Intervention study for smoking cessation in diabetic patients: a randomized controlled trial in both clinical and primary care settings. Diabetes Care 23 (2000), 1455–1460.
Weissfeld, J.L., Holloway, J.L., Treatment for cigarette smoking in a Department of Veterans Affairs outpatient clinic. Arch Intern Med 151 (1991), 973–977.
Bock, B., Heron, K., Jennings, E., Morrow, K., Cobb, V., Magee, J., et al. A text message delivered smoking cessation intervention: the initial trial of TXT-2-Quit: randomized controlled trial. JMIR Mhealth Uhealth, 1, 2013, e17.
Smith, B.J., Carson, K.V., Brinn, M.P., Labiszewski, N.A., Peters, M.J., Fitridge, R., et al. Smoking Termination Opportunity for inPatients (STOP): superiority of a course of varenicline tartrate plus counselling over counselling alone for smoking cessation: a 12-month randomised controlled trial for inpatients. Thorax 68 (2013), 485–486.
Carson-Chahhoud, K.V., Smith, B.J., Peters, M.J., Brinn, M.P., Ameer, F., Singh, K., et al. Two-year efficacy of varenicline tartrate and counselling for inpatient smoking cessation (STOP study): a randomized controlled clinical trial. PLoS One, 15, 2020, e0231095.
Hennrikus, D., Joseph, A.M., Lando, H.A., Duval, S., Ukestad, L., Kodl, M., et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol 56 (2010), 2105–2112.
Goodney, P.P., Spangler, E.L., Newhall, K., Brooke, B.S., Schanzer, A., Tan, T.W., et al. Feasibility and pilot efficacy of a brief smoking cessation intervention delivered by vascular surgeons in the Vascular Physician Offer and Report (VAPOR) Trial. J Vasc Surg 65 (2017), 1152–11560 e2.
Visseren, F.L.J., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., Back, M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol 29 (2022), 5–115.
Lopez-Laguna, N., Martinez-Gonzalez, M.A., Toledo, E., Babio, N., Sorli, J.V., Ros, E., et al. Risk of peripheral artery disease according to a healthy lifestyle score: the PREDIMED study. Atherosclerosis 275 (2018), 133–140.
Tharrey, M., Mariotti, F., Mashchak, A., Barbillon, P., Delattre, M., Fraser, G.E., Patterns of plant and animal protein intake are strongly associated with cardiovascular mortality: the Adventist Health Study-2 cohort. Int J Epidemiol 47 (2018), 1603–1612.
Sotos-Prieto, M., Bhupathiraju, S.N., Mattei, J., Fung, T.T., Li, Y., Pan, A., et al. Association of changes in diet quality with total and cause-specific mortality. N Engl J Med 377 (2017), 143–153.
Adegbola, A., Behrendt, C.A., Zyriax, B.C., Windler, E., Kreutzburg, T., The impact of nutrition on the development and progression of peripheral artery disease: a systematic review. Clin Nutr 41 (2022), 49–70.
Mahe, G., Carsin, M., Zeeny, M., De Bosschere, J.P., Dietary pattern, a modifiable risk factor that can be easily assessed for atherosclerosis vascular disease prevention in clinical practice. Public Health Nutr 14 (2011), 319–326.
Lee, W.W., Choi, K.C., Yum, R.W., Yu, D.S., Chair, S.Y., Effectiveness of motivational interviewing on lifestyle modification and health outcomes of clients at risk or diagnosed with cardiovascular diseases: a systematic review. Int J Nurs Stud 53 (2016), 331–341.
Van Horn, L., Carson, J.A., Appel, L.J., Burke, L.E., Economos, C., Karmally, W., et al. Recommended dietary pattern to achieve adherence to the American Heart Association/American College of Cardiology (AHA/ACC) Guidelines: a Scientific Statement From the American Heart Association. Circulation 134 (2016), e505–e529.
Mattioli, A.V., Coppi, F., Migaldi, M., Scicchitano, P., Ciccone, M.M., Farinetti, A., Relationship between Mediterranean diet and asymptomatic peripheral arterial disease in a population of pre-menopausal women. Nutr Metab Cardiovasc Dis 27 (2017), 985–990.
Martinez-Gonzalez, M.A., Salas-Salvado, J., Estruch, R., Corella, D., Fito, M., Ros, E., et al. Benefits of the Mediterranean Diet: insights from the PREDIMED Study. Prog Cardiovasc Dis 58 (2015), 50–60.
Fowkes, F.G.R., Rudan, D., Rudan, I., Aboyans, V., Denenberg, J.O., McDermott, M.M., et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 382 (2013), 1329–1340.
Rollason, V., Vogt, N., Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 20 (2003), 817–832.
Katsimpris, A., Linseisen, J., Meisinger, C., Volaklis, K., The association between polypharmacy and physical function in older adults: a systematic review. J Gen Intern Med 34 (2019), 1865–1873.
Davies, L.E., Spiers, G., Kingston, A., Todd, A., Adamson, J., Hanratty, B., Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc 21 (2020), 181–187.
Masson, W., Lobo, M., Barbagelata, L., Molinero, G., Bluro, I., Effects of lipid-lowering therapy on major adverse limb events in patients with peripheral arterial disease: a meta-analysis of randomized clinical trials. Vascular 30 (2022), 1134–1141.
Nastasi, D.R., Moxon, J.V., Norman, R., Trollope, A.F., Rowbotham, S., Quigley, F., et al. The cost-effectiveness of intensive low-density lipoprotein cholesterol lowering in people with peripheral artery disease. J Vasc Surg 73 (2021), 1396–13403 e3.
Hess, C.N., Cannon, C.P., Beckman, J.A., Goodney, P.P., Patel, M.R., Hiatt, W.R., et al. Effectiveness of blood lipid management in patients with peripheral artery disease. J Am Coll Cardiol 77 (2021), 3016–3027.
Ference, B.A., Ginsberg, H.N., Graham, I., Ray, K.K., Packard, C.J., Bruckert, E., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 38 (2017), 2459–2472.
Boren, J., Chapman, M.J., Krauss, R.M., Packard, C.J., Bentzon, J.F., Binder, C.J., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 41 (2020), 2313–2330.
Mach, F., Baigent, C., Catapano, A.L., Koskinas, K.C., Casula, M., Badimon, L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 41 (2020), 111–188.
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388 (2016), 2532–2561.
Foley, T.R., Singh, G.D., Kokkinidis, D.G., Choy, H.K., Pham, T., Amsterdam, E.A., et al. High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc, 6, 2017, e005699.
Giugliano, R.P., Cannon, C.P., Blazing, M.A., Nicolau, J.C., Corbalan, R., Spinar, J., et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 137 (2018), 1571–1582.
Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372 (2015), 2387–2397.
Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376 (2017), 1713–1722.
Sabatine, M.S., Leiter, L.A., Wiviott, S.D., Giugliano, R.P., Deedwania, P., De Ferrari, G.M., et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol 5 (2017), 941–950.
Bonaca, M.P., Nault, P., Giugliano, R.P., Keech, A.C., Pineda, A.L., Kanevsky, E., et al. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation 137 (2018), 338–350.
Laschkolnig, A., Kollerits, B., Lamina, C., Meisinger, C., Rantner, B., Stadler, M., et al. Lipoprotein (a) concentrations, apolipoprotein (a) phenotypes, and peripheral arterial disease in three independent cohorts. Cardiovasc Res 103 (2014), 28–36.
Antoniou, G.A., Hajibandeh, S., Hajibandeh, S., Vallabhaneni, S.R., Brennan, J.A., Torella, F., Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. J Vasc Surg 61 (2015), 519–532 e1.
Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 (2007), 645–654 discussion 653–4.
Kumbhani, D.J., Steg, P.G., Cannon, C.P., Eagle, K.A., Smith, S.C. Jr., Goto, S., et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 35 (2014), 2864–2872.
Peters, F., Kuchenbecker, J., Kreutzburg, T., Marschall, U., Debus, E.S., Behrendt, C.A., Long-term effectiveness and safety of initiating statin therapy after index revascularization in patients with peripheral arterial occlusive disease. J Am Heart Assoc, 9, 2020, e018338.
Ramos, R., Garcia-Gil, M., Comas-Cufi, M., Quesada, M., Marrugat, J., Elosua, R., et al. Statins for prevention of cardiovascular events in a low-risk population with low ankle brachial index. J Am Coll Cardiol 67 (2016), 630–640.
Vogel, T.R., Dombrovskiy, V.Y., Galinanes, E.L., Kruse, R.L., Preoperative statins and limb salvage after lower extremity revascularization in the Medicare population. Circ Cardiovasc Interv 6 (2013), 694–700.
Mills, E.J., Wu, P., Chong, G., Ghement, I., Singh, S., Akl, E.A., et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM 104 (2011), 109–124.
Rodriguez, F., Maron, D.J., Knowles, J.W., Virani, S.S., Lin, S., Heidenreich, P.A., Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol 2 (2017), 47–54.
De Martino, R.R., Eldrup-Jorgensen, J., Nolan, B.W., Stone, D.H., Adams, J., Bertges, D.J., et al. Perioperative management with antiplatelet and statin medication is associated with reduced mortality following vascular surgery. J Vasc Surg 59 (2014), 1615–1621 21 e1.
Baigent, C., Keech, A., Kearney, P.M., Blackwell, L., Buck, G., Pollicino, C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005), 1267–1278.
Cholesterol Treatment Trialists Collaborators, Fulcher J O'Connell, R., Voysey, M., Emberson, J., Blackwell, L., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385 (2015), 1397–1405.
Leya, M., Stone, N.J., Statin prescribing in the elderly: special considerations. Curr Atheroscler Rep, 19, 2017, 47.
Kokkinidis, D.G., Arfaras-Melainis, A., Giannopoulos, S., Katsaros, I., Jawaid, O., Jonnalagadda, A.K., et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis. Vasc Med 25 (2020), 106–117.
Sigvant, B., Wiberg-Hedman, K., Bergqvist, D., Rolandsson, O., Wahlberg, E., Risk factor profiles and use of cardiovascular drug prevention in women and men with peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 16 (2009), 39–46.
Belch, J.J.F., Brodmann, M., Baumgartner, I., Binder, C.J., Casula, M., Heiss, C., et al. Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease. Vasa 50 (2021), 401–411.
Bavry, A.A., Anderson, R.D., Gong, Y., Denardo, S.J., Cooper-Dehoff, R.M., Handberg, E.M., et al. Outcomes Among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 55 (2010), 48–53.
Feringa, H.H., van Waning, V.H., Bax, J.J., Elhendy, A., Boersma, E., Schouten, O., et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol 47 (2006), 1182–1187.
Ostergren, J., Sleight, P., Dagenais, G., Danisa, K., Bosch, J., Qilong, Y., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 25 (2004), 17–24.
Otterstad, J.E., Sleight, P., The HOPE study: comparison with other trials of secondary prevention. Eur Heart J 22 (2001), 1307–1310.
Sleight, P., The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 1 (2000), 18–20.
Heart Outcomes Prevention Evaluation Study Investigators Yusuf, S., Sleight, P., Pogue, J., Bosch, J., Davies, R., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000), 145–153.
Yusuf, S., Diener, H.C., Sacco, R.L., Cotton, D., Ounpuu, S., Lawton, W.A., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 (2008), 1225–1237.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002), 2981–2997.
Lewington, S., Clarke, R., Qizilbash, N., Peto, R., Collins, R., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002), 1903–1913.
Geldsetzer, P., Manne-Goehler, J., Marcus, M.E., Ebert, C., Zhumadilov, Z., Wesseh, C.S., et al. The state of hypertension care in 44 low-income and middle-income countries: a cross-sectional study of nationally representative individual-level data from 1.1 million adults. Lancet 394 (2019), 652–662.
NCD Risk Factor Collaboration. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet 394 (2019), 639–651.
Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C., Catapano, A.L., et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 37 (2016), 2315–2381.
He, F.J., Li, J., Macgregor, G.A., Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ, 346, 2013, f1325.
Gay, H.C., Rao, S.G., Vaccarino, V., Ali, M.K., Effects of different dietary interventions on blood pressure: systematic review and meta-analysis of randomized controlled trials. Hypertension 67 (2016), 733–739.
Roerecke, M., Kaczorowski, J., Tobe, S.W., Gmel, G., Hasan, O.S.M., Rehm, J., The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health 2 (2017), e108–e120.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens 36 (2018), 1953–2041.
Unger, T., Borghi, C., Charchar, F., Khan, N.A., Poulter, N.R., Prabhakaran, D., et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension 75 (2020), 1334–1357.
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., et al. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Blood Press 27 (2018), 314–340.
Diehm, C., Pittrow, D., Lawall, H., Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens 29 (2011), 1448–1456.
Paravastu, S.C., Mendonca, D.A., Da Silva, A., Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev, 2013, 2013, CD005508.
Espinola-Klein, C., Weisser, G., Jagodzinski, A., Savvidis, S., Warnholtz, A., Ostad, M.A., et al. beta-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 58 (2011), 148–154.
Visseren, F.L.J., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., Back, M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42 (2021), 3227–3337.
Williams, B., Mancia, G., Spiering, W., Rosei, E.A., Azizi, M., Burnier, M., et al. [2018 ESC/ESH Guidelines for the management of arterial hypertension]. Kardiol Pol 77 (2019), 71–159.
Kleinherenbrink, W., Osei, E., den Hertog, H.M., Zandbergen, A.A.M., Prediabetes and macrovascular disease: review of the association, influence on outcome and effect of treatment. Eur J Intern Med 55 (2018), 6–11.
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41 (2020), 255–323.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021. Diabetes Care 44 (2021), S111–S124.
Palmer, S.C., Mavridis, D., Nicolucci, A., Johnson, D.W., Tonelli, M., Craig, J.C., et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 316 (2016), 313–324.
Escobar, C., Barrios, V., Cosin, J., Gamez Martinez, J.M., Huelmos Rodrigo, A.I., Ortiz Cortes, C., et al. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: a systematic review. Diabet Med, 38, 2021, e14502.
Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Furtado, R.H.M., et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139 (2019), 2022–2031.
Kristensen, S.L., Rorth, R., Jhund, P.S., Docherty, K.F., Sattar, N., Preiss, D., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (2019), 776–785.
Marchiori, E., Rodionov, R.N., Peters, F., Magnussen, C., Nordanstig, J., Gombert, A., et al. SGLT2 inhibitors and peripheral vascular events: a review of the literature. Heart Fail Clin 18 (2022), 609–623.
Heerspink, H.J.L., Stefansson, B.V., Correa-Rotter, R., Chertow, G.M., Greene, T., Hou, F.F., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383 (2020), 1436–1446.
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., Kober, L., Kosiborod, M.N., Martinez, F.A., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 (2019), 1995–2008.
Vlachopoulos, C., Terentes-Printzios, D., Tsioufis, K., Do SGLT2 inhibitors increase the risk of amputation? Make haste slowly. Eur Heart J 42 (2021), 1739–1741.
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 837–853.
Diabetes Control and Complications Trial Research Group Nathan, D.M., Genuth, S., Lachin, J., Cleary, P., et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
Holman, R.R., Paul, S.K., Bethel, M.A., Neil, H.A., Matthews, D.R., Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 (2008), 1565–1576.
Holman, R.R., Paul, S.K., Bethel, M.A., Matthews, D.R., Neil, H.A., 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008), 1577–1589.
Demicheli, V., Jefferson, T., Di Pietrantonj, C., Ferroni, E., Thorning, S., Thomas, R.E., et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev, 2, 2018, CD004876.
Peters, F., Marschall, U., Behrendt, C.A., Prevalence of COVID-19 risk factors and risks of severe acute respiratory disease are markedly higher in patients with symptomatic peripheral arterial occlusive disease. Eur J Vasc Endovasc Surg 61 (2021), 859–860.
Gurfinkel, E.P., Leon de la Fuente, R., Mendiz, O., Mautner, B., Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study. Eur Heart J 25 (2004), 25–31.
Ciszewski, A., Bilinska, Z.T., Brydak, L.B., Kepka, C., Kruk, M., Romanowska, M., et al. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study. Eur Heart J 29 (2008), 1350–1358.
Smolderen, K.G., Lee, M., Arora, T., Simonov, M., Mena-Hurtado, C., Peripheral artery disease and COVID-19 outcomes: insights from the Yale DOM-CovX Registry. Curr Probl Cardiol, 47, 2022, 101007.
Jongkind, V., Earnshaw, J.J., Bastos Goncalves, F., Cochennec, F., Debus, E.S., Hinchliffe, R., et al. Editor's Choice - Update of the European Society for Vascular Surgery (ESVS) 2020 Clinical Practice Guidelines on the Management of Acute Limb Ischaemia in light of the COVID-19 pandemic, based on a scoping review of the literature. Eur J Vasc Endovasc Surg 63 (2022), 80–89.
Gal, D., Thijs, B., Glanzel, W., Sipido, K.R., Hot topics and trends in cardiovascular research. Eur Heart J 40 (2019), 2363–2374.
Suarez, C., Zeymer, U., Limbourg, T., Baumgartner, I., Cacoub, P., Poldermans, D., et al. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry. Vasc Med 15 (2010), 259–265.
Mahe, G., Boge, G., Bura-Riviere, A., Chakfe, N., Constans, J., Goueffic, Y., et al. Disparities between international guidelines (AHA/ESC/ESVS/ESVM/SVS) concerning lower extremity arterial disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). Ann Vasc Surg 72 (2021), 1–56.
McDermott, M.M., Fried, L., Simonsick, E., Ling, S., Guralnik, J.M., Asymptomatic peripheral arterial disease is independently associated with impaired lower extremity functioning: the Women's Health and Aging Study. Circulation 101 (2000), 1007–1012.
McDermott, M.M., Liu, K., Greenland, P., Guralnik, J.M., Criqui, M.H., Chan, C., et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 292 (2004), 453–461.
McDermott, M.M., Tiukinhoy, S., Greenland, P., Liu, K., Pearce, W.H., Guralnik, J.M., et al. A pilot exercise intervention to improve lower extremity functioning in peripheral arterial disease unaccompanied by intermittent claudication. J Cardiopulm Rehabil 24 (2004), 187–196.
Laslovich, S., Alvar, B.A., Allison, M., Rauh, M.J., Effects of lifestyle physical activity on vascular function in asymptomatic peripheral arterial disease. Med Sci Sports Exerc 52 (2020), 8–15.
Farhad, A., Farooqui, S.I., Amjad, S., Khan, A.A., Role of structured and supervised exercise programmes in peripheral artery disease patients with and without claudication - a systematic review and metaanalysis. J Pak Med Assoc 69 (2019), 874–878.
McDermott, M.M., Ades, P., Guralnik, J.M., Dyer, A., Ferrucci, L., Liu, K., et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 301 (2009), 165–174.
McDermott, M.M., Liu, K., Guralnik, J.M., Criqui, M.H., Spring, B., Tian, L., et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 310 (2013), 57–65.
Itoga, N.K., Minami, H.R., Chelvakumar, M., Pearson, K., Mell, M.M., Bendavid, E., et al. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. Vasc Med 23 (2018), 97–106.
Visseren, F.L.J., Mach, F., Smulders, Y.M., Carballo, D., Koskinas, K.C., Back, M., et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 42 (2021), 3227–3337.
Kraus, W.E., Powell, K.E., Haskell, W.L., Janz, K.F., Campbell, W.W., Jakicic, J.M., et al. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med Sci Sports Exerc 51 (2019), 1270–1281.
Powell, K.E., King, A.C., Buchner, D.M., Campbell, W.W., DiPietro, L., Erickson, K.I., et al. The Scientific Foundation for the Physical Activity Guidelines for Americans, 2nd Edition. J Phys Act Health, 2018, 1–11.
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
Fowkes, F.G., Price, J.F., Stewart, M.C., Butcher, I., Leng, G.C., Pell, A.C., et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303 (2010), 841–848.
Ambler, G.K., Waldron, C.A., Contractor, U.B., Hinchliffe, R.J., Twine, C.P., Umbrella review and meta-analysis of antiplatelet therapy for peripheral artery disease. Br J Surg 107 (2020), 20–32.
Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
Sigvant, B., Henriksson, M., Lundin, F., Wahlberg, E., Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective?. Eur J Cardiovasc Prev Rehabil 18 (2011), 254–261.
Heald, C.L., Fowkes, F.G., Murray, G.D., Price, J.F., Ankle Brachial Index, C., Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis 189 (2006), 61–69.
Qu, B., Liu, Q., Li, J., Systematic review of association between low ankle-brachial index and all-cause cardiovascular, or non-cardiovascular mortality. Cell Biochem Biophys 73 (2015), 571–575.
Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., Barshes, N.R., Corriere, M.A., Drachman, D.E., et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 135 (2017), e686–e725.
Mazari, F.A., Khan, J.A., Carradice, D., Samuel, N., Gohil, R., McCollum, P.T., et al. Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg 100 (2013), 1172–1179.
Nordanstig, J., Taft, C., Hensater, M., Perlander, A., Osterberg, K., Jivegard, L., Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial. Circulation 130 (2014), 939–947.
Nordanstig, J., Taft, C., Hensater, M., Perlander, A., Osterberg, K., Jivegard, L., Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication. Br J Surg 103 (2016), 1290–1299.
Djerf, H., Millinger, J., Falkenberg, M., Jivegard, L., Svensson, M., Nordanstig, J., Absence of long-term benefit of revascularization in patients with intermittent claudication: five-year results from the IRONIC randomized controlled trial. Circ Cardiovasc Interv, 13, 2020, e008450.
Reynolds, M.R., Apruzzese, P., Galper, B.Z., Murphy, T.P., Hirsch, A.T., Cutlip, D.E., et al. Cost-effectiveness of supervised exercise, stenting, and optimal medical care for claudication: results from the Claudication: Exercise Versus Endoluminal Revascularization (CLEVER) trial. J Am Heart Assoc, 3, 2014, e001233.
Spronk, S., Bosch, J.L., den Hoed, P.T., Veen, H.F., Pattynama, P.M., Hunink, M.G., Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg 48 (2008), 1472–1480.
Fokkenrood, H.J., Scheltinga, M.R., Koelemay, M.J., Breek, J.C., Hasaart, F., Vahl, A.C., et al. Significant savings with a stepped care model for treatment of patients with intermittent claudication. Eur J Vasc Endovasc Surg 48 (2014), 423–429.
van den Houten, M.M., Lauret, G.J., Fakhry, F., Fokkenrood, H.J., van Asselt, A.D., Hunink, M.G., et al. Cost-effectiveness of supervised exercise therapy compared with endovascular revascularization for intermittent claudication. Br J Surg 103 (2016), 1616–1625.
Fakhry, F., Rouwet, E.V., Spillenaar Bilgen, R., van der Laan, L., Wever, J.J., Teijink, J.A.W., et al. Endovascular revascularization plus supervised exercise versus supervised exercise only for intermittent claudication: a cost-effectiveness analysis. Circ Cardiovasc Interv, 14, 2021, e010703.
Hageman, D., Fokkenrood, H.J.P., Essers, P.P.M., Koelemay, M.J.W., Breek, J.C., Vahl, A.C., et al. Improved adherence to a stepped-care model reduces costs of intermittent claudication treatment in the Netherlands. Eur J Vasc Endovasc Surg 54 (2017), 51–57.
Treesak, C., Kasemsup, V., Treat-Jacobson, D., Nyman, J.A., Hirsch, A.T., Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med 9 (2004), 279–285.
de Vries, S.O., Visser, K., de Vries, J.A., Wong, J.B., Donaldson, M.C., Hunink, M.G., Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 222 (2002), 25–36.
Koelemay, M.J.W., van Reijen, N.S., van Dieren, S., Frans, F.A., Vermeulen, E.J.G., Buscher, H., et al. Editor's Choice - Randomised clinical trial of supervised exercise therapy vs. endovascular revascularisation for intermittent claudication caused by iliac artery obstruction: the SUPER study. Eur J Vasc Endovasc Surg 63 (2022), 421–429.
van Reijen, N.S., van Dieren, S., Frans, F.A., Reekers, J.A., Metz, R., Buscher, H., et al. Cost effectiveness of endovascular revascularisation vs. exercise therapy for intermittent claudication due to iliac artery obstruction. Eur J Vasc Endovasc Surg 63 (2022), 430–437.
Lauret, G.J., Gijsbers, H.J., Hendriks, E.J., Bartelink, M.L., de Bie, R.A., Teijink, J.A., The ClaudicatioNet concept: design of a national integrated care network providing active and healthy aging for patients with intermittent claudication. Vasc Health Risk Manag 8 (2012), 495–503.
Jansen, S.C.P., van Nistelrooij, L.P.J., Scheltinga, M.R.M., Rouwet, E.V., Teijink, J.A.W., Vahl, A.C., Successful implementation of the exercise first approach for intermittent claudication in the Netherlands is associated with few lower limb revascularisations. Eur J Vasc Endovasc Surg 60 (2020), 881–887.
Mazari, F.A.K., Khan, J.A., Carradice, D., Samuel, N., Gohil, R., McCollum, P.T., et al. Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg 100 (2013), 1172–1179.
Spronk, S., Bosch, J.L., den Hoed, P.T., Veen, H.F., Pattynama, P.M.T., Hunink, M.G.M., Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg 48 (2008), 1472–1480.
Treat-Jacobson, D., McDermott, M.M., Bronas, U.G., Campia, U., Collins, T.C., Criqui, M.H., et al. Optimal exercise programs for patients with peripheral artery disease: a Scientific Statement from the American Heart Association. Circulation 139 (2019), e10–e33.
Rodrigues, E., Silva, I., Supervised exercise therapy in intermittent claudication: a systematic review of clinical impact and limitations. Int Angiol 39 (2020), 60–75.
Harwood, A.E., Cayton, T., Sarvanandan, R., Lane, R., Chetter, I., A review of the potential local mechanisms by which exercise improves functional outcomes in intermittent claudication. Ann Vasc Surg 30 (2016), 312–320.
Lane, R., Harwood, A., Watson, L., Leng, G.C., Exercise for intermittent claudication. Cochrane Database Syst Rev, 12, 2017, CD000990.
Parmenter, B.J., Dieberg, G., Smart, N.A., Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 45 (2015), 231–244.
Hageman, D., Fokkenrood, H.J., Gommans, L.N., van den Houten, M.M., Teijink, J.A., Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev, 4, 2018, CD005263.
Vemulapalli, S., Dolor, R.J., Hasselblad, V., Schmit, K., Banks, A., Heidenfelder, B., et al. Supervised vs unsupervised exercise for intermittent claudication: a systematic review and meta-analysis. Am Heart J 169 (2015), 924–937 e3.
Gommans, L.N., Saarloos, R., Scheltinga, M.R., Houterman, S., de Bie, R.A., Fokkenrood, H.J., et al. Editor's choice–The effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 48 (2014), 169–184.
Parmenter, B.J., Dieberg, G., Phipps, G., Smart, N.A., Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med 20 (2015), 30–40.
Fakhry, F., van de Luijtgaarden, K.M., Bax, L., den Hoed, P.T., Hunink, M.G., Rouwet, E.V., et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg 56 (2012), 1132–1142.
Pymer, S., Ibeggazene, S., Palmer, J., Tew, G.A., Ingle, L., Smith, G.E., et al. An updated systematic review and meta-analysis of home-based exercise programs for individuals with intermittent claudication. J Vasc Surg 74 (2021), 2076–2085 e20.
Gommans, L.N., Fokkenrood, H.J., van Dalen, H.C., Scheltinga, M.R., Teijink, J.A., Peters, R.J., Safety of supervised exercise therapy in patients with intermittent claudication. J Vasc Surg 61 (2015), 512–518 e2.
Gommans, L.N.M., Saarloos, R., Scheltinga, M.R.M., Houterman, S., de Bie, R.A., Fokkenrood, H.J.P., et al. Editor's choice–The effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 48 (2014), 169–184.
Makris, G.C., Lattimer, C.R., Lavida, A., Geroulakos, G., Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg 44 (2012), 569–575 discussion 76.
Dua, A., Gologorsky, R., Savage, D., Rens, N., Gandhi, N., Brooke, B., et al. National assessment of availability, awareness, and utilization of supervised exercise therapy for peripheral artery disease patients with intermittent claudication. J Vasc Surg 71 (2020), 1702–1707.
Abaraogu, U.O., Abaraogu, O.D., Dall, P.M., Tew, G., Stuart, W., Brittenden, J., et al. Exercise therapy in routine management of peripheral arterial disease and intermittent claudication: a scoping review. Ther Adv Cardiovasc Dis, 14, 2020, 1753944720924270.
Golledge, J., Singh, T.P., Alahakoon, C., Pinchbeck, J., Yip, L., Moxon, J.V., et al. Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease. Br J Surg 106 (2019), 319–331.
Jansen, S.C., Abaraogu, U.O., Lauret, G.J., Fakhry, F., Fokkenrood, H.J., Teijink, J.A., Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev, 8, 2020, CD009638.
Galea, M.N., Bray, S.R., Ginis, K.A., Barriers and facilitators for walking in individuals with intermittent claudication. J Aging Phys Act 16 (2008), 69–83 quiz 84.
Seed, S.A., Harwood, A.E., Sinclair, J., Pymer, S., Caldow, E., Ingle, L., et al. A systematic review of exercise prescription in patients with intermittent claudication: does pain matter?. Ann Vasc Surg 77 (2021), 315–323.
Perks, J., Zaccardi, F., Paterson, C., Houghton, J.S.M., Nickinson, A.T.O., Pepper, C.J., et al. Effect of high-pain versus low-pain structured exercise on walking ability in people with intermittent claudication: meta-analysis. Br J Surg 109 (2022), 686–694.
Fassora, M., Calanca, L., Jaques, C., Mazzolai, L., Kayser, B., Lanzi, S., Intensity-dependent effects of exercise therapy on walking performance and aerobic fitness in symptomatic patients with lower-extremity peripheral artery disease: a systematic review and meta-analysis. Vasc Med 27 (2022), 158–170.
McDermott, M.M., Spring, B., Tian, L., Treat-Jacobson, D., Ferrucci, L., Lloyd-Jones, D., et al. Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial. JAMA 325 (2021), 1266–1276.
Lanzi, S., Belch, J., Brodmann, M., Madaric, J., Bura-Riviere, A., Visona, A., et al. Supervised exercise training in patients with lower extremity peripheral artery disease. Vasa 51 (2022), 267–274.
Harwood, A.E., Smith, G.E., Cayton, T., Broadbent, E., Chetter, I.C., A systematic review of the uptake and adherence rates to supervised exercise programs in patients with intermittent claudication. Ann Vasc Surg 34 (2016), 280–289.
Sandberg, A., Back, M., Cider, A., Jivegard, L., Sigvant, B., Wittboldt, S., et al. Effectiveness of supervised exercise, home-based exercise, or walk advice strategies on walking performance and muscle endurance in patients with intermittent claudication (SUNFIT trial): a randomized clinical trial. Eur J Cardiovasc Nurs 22 (2023), 400–411.
Lauret, G.J., van Dalen, D.C., Willigendael, E.M., Hendriks, E.J., de Bie, R.A., Spronk, S., et al. Supervised exercise therapy for intermittent claudication: current status and future perspectives. Vascular 20 (2012), 12–19.
Hageman, D., van den Houten, M.M., Spruijt, S., Gommans, L.N., Scheltinga, M.R., Teijink, J.A., Supervised exercise therapy: it does work, but how to set up a program?. J Cardiovasc Surg (Torino) 58 (2017), 305–312.
Treat-Jacobson, D., McDermott, M.M., Beckman, J.A., Burt, M.A., Creager, M.A., Ehrman, J.K., et al. Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: a Science Advisory from the American Heart Association. Circulation 140 (2019), e700–e710.
Ambrosetti, M., Abreu, A., Corra, U., Davos, C.H., Hansen, D., Frederix, I., et al. Secondary prevention through comprehensive cardiovascular rehabilitation: From knowledge to implementation. 2020 update. A position paper from the Secondary Prevention and Rehabilitation Section of the European Association of Preventive Cardiology. Eur J Prev Cardiol 28 (2021), 460–495.
Ambrosetti, M., Temporelli, P.L., Faggiano, P., Febo, O., Diaco, T., Favretto, G., et al. Lower extremities peripheral arterial disease among patients admitted to cardiac rehabilitation: the THINKPAD registry. Int J Cardiol 171 (2014), 192–198.
Siercke, M., Jorgensen, L.P., Missel, M., Thygesen, L.C., Moller, S.P., Sillesen, H., et al. Cardiovascular rehabilitation increases walking distance in patients with intermittent claudication. results of the CIPIC Rehab Study: a randomised controlled trial. Eur J Vasc Endovasc Surg 62 (2021), 768–776.
Devrome, A.N., Aggarwal, S., McMurtry, M.S., Southern, D., Hauer, T., Lamb, B., et al. Cardiac rehabilitation in people with peripheral arterial disease: a higher risk population that benefits from completion. Int J Cardiol 285 (2019), 108–114.
Nguyen, C.H., Marzolini, S., Oh, P., Thomas, S.G., A retrospective comparison of fitness and exercise progression in patients with coronary and peripheral artery disease in cardiac rehabilitation. Can J Cardiol 37 (2021), 260–268.
Jeger, R.V., Rickenbacher, P., Pfisterer, M.E., Hoffmann, A., Outpatient rehabilitation in patients with coronary artery and peripheral arterial occlusive disease. Arch Phys Med Rehabil 89 (2008), 618–621.
Stauber, S., Guera, V., Barth, J., Schmid, J.P., Saner, H., Znoj, H., et al. Psychosocial outcome in cardiovascular rehabilitation of peripheral artery disease and coronary artery disease patients. Vasc Med 18 (2013), 257–262.
Saratzis, A., Paraskevopoulos, I., Patel, S., Donati, T., Biasi, L., Diamantopoulos, A., et al. Supervised exercise therapy and revascularization for intermittent claudication: network meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 12 (2019), 1125–1136.
Klaphake, S., Buettner, S., Ultee, K.H., van Rijn, M.J., Hoeks, S.E., Verhagen, H.J., Combination of endovascular revascularization and supervised exercise therapy for intermittent claudication: a systematic review and meta-analysis. J Cardiovasc Surg (Torino) 59 (2018), 150–157.
Meneses, A.L., Ritti-Dias, R.M., Parmenter, B., Golledge, J., Askew, C.D., Combined lower limb revascularisation and supervised exercise training for patients with peripheral arterial disease: a systematic review of randomised controlled trials. Sports Med 47 (2017), 987–1002.
Vemulapalli, S., Revascularisation plus supervised exercise is superior to supervised exercise alone for the treatment of intermittent claudication. Evid Based Med, 21, 2016, 91.
Aherne, T., McHugh, S., Kheirelseid, E.A., Lee, M.J., McCaffrey, N., Moneley, D., et al. Comparing supervised exercise therapy to invasive measures in the management of symptomatic peripheral arterial disease. Surg Res Pract, 2015, 2015, 960402.
Doshi, R., Shah, P., Majmundar, M., Kumar, A., Vallabhajosyula, S., Comparison of supervised exercise therapy with or without revascularization for the management of intermittent claudication: SET in PAD. Eur J Intern Med 92 (2021), 131–133.
Bo, E., Hisdal, J., Cvancarova, M., Stranden, E., Jorgensen, J.J., Sandbaek, G., et al. Twelve-months follow-up of supervised exercise after percutaneous transluminal angioplasty for intermittent claudication: a randomised clinical trial. Int J Environ Res Public Health 10 (2013), 5998–6014.
Klaphake, S., Fakhry, F., Rouwet, E.V., van der Laan, L., Wever, J.J., Teijink, J.A., et al. Long-term follow-up of a randomized clinical trial comparing endovascular revascularization plus supervised exercise with supervised exercise only for intermittent claudication. Ann Surg 276 (2022), e1035–e1043.
Fakhry, F., Spronk, S., van der Laan, L., Wever, J.J., Teijink, J.A., Hoffmann, W.H., et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA 314 (2015), 1936–1944.
Thanigaimani, S., Phie, J., Sharma, C., Wong, S., Ibrahim, M., Huynh, P., et al. Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials. J Am Heart Assoc, 10, 2021, e019672.
Saratzis, A., Paraskevopoulos, I., Patel, S., Donati, T., Biasi, L., Diamantopoulos, A., et al. Supervised exercise therapy and revascularization for intermittent claudication: network meta-analysis of randomized controlled trials. JACC Cardiovasc Interv 12 (2019), 1125–1136.
Bø, E., Hisdal, J., Cvancarova, M., Stranden, E., Jørgensen, J.J., Sandbæk, G., et al. Twelve-months follow-up of supervised exercise after percutaneous transluminal angioplasty for intermittent claudication: a randomised clinical trial. Int J Environ Res Public Health 10 (2013), 5998–6014.
Kruidenier, L.M., Nicolai, S.P., Rouwet, E.V., Peters, R.J., Prins, M.H., Teijink, J.A., Additional supervised exercise therapy after a percutaneous vascular intervention for peripheral arterial disease: a randomized clinical trial. J Vasc Interv Radiol 22 (2011), 961–968.
Abaraogu, U.O., Dall, P.M., Seenan, C.A., The effect of structured patient education on physical activity in patients with peripheral arterial disease and intermittent claudication: a systematic review. Eur J Vasc Endovasc Surg 54 (2017), 58–68.
McCallum, M., Cooper, B., Matson, S., Renwick, B., Messeder, S.J., Improving health behaviors in patients with peripheral arterial disease - a pilot study of supported self-management. J Vasc Nurs 39 (2021), 11–16.
Cunningham, M.A., Swanson, V., Holdsworth, R.J., O'Carroll, R.E., Late effects of a brief psychological intervention in patients with intermittent claudication in a randomized clinical trial. Br J Surg 100 (2013), 756–760.
Cunningham, M.A., Swanson, V., O'Carroll, R.E., Holdsworth, R.J., Randomized clinical trial of a brief psychological intervention to increase walking in patients with intermittent claudication. Br J Surg 99 (2012), 49–56.
Momsen, A.H., Jensen, M.B., Norager, C.B., Madsen, M.R., Vestersgaard-Andersen, T., Lindholt, J.S., Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 38 (2009), 463–474.
Stevens, J.W., Simpson, E., Harnan, S., Squires, H., Meng, Y., Thomas, S., et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 99 (2012), 1630–1638.
Bedenis, R., Stewart, M., Cleanthis, M., Robless, P., Mikhailidis, D.P., Stansby, G., Cilostazol for intermittent claudication. Cochrane Database Syst Rev, 2014, 2014, CD003748.
Brown, T., Forster, R.B., Cleanthis, M., Mikhailidis, D.P., Stansby, G., Stewart, M., Cilostazol for intermittent claudication. Cochrane Database Syst Rev, 6, 2021, CD003748.
Salhiyyah, K., Forster, R., Senanayake, E., Abdel-Hadi, M., Booth, A., Michaels, J.A., Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev, 9, 2015, CD005262.
Salhiyyah, K., Senanayake, E., Abdel-Hadi, M., Booth, A., Michaels, J.A., Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev, 1, 2012, CD005262.
Dawson, D.L., Cutler, B.S., Hiatt, W.R., Hobson, R.W. 2nd, Martin, J.D., Bortey, E.B., et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109 (2000), 523–530.
Ruffolo, A.J., Romano, M., Ciapponi, A., Prostanoids for critical limb ischaemia. 2010, Cochrane Database Syst Rev, CD006544.
Robertson, L., Andras, A., Prostanoids for intermittent claudication. 2013, Cochrane Database Syst Rev, CD000986.
Levin, S.R., Farber, A., Cheng, T.W., Arinze, N., Jones, D.W., Rybin, D., et al. Patients undergoing interventions for claudication experience low perioperative morbidity but are at risk for worsening functional status and limb loss. J Vasc Surg 72 (2020), 241–249.
Klein, W.M., van der Graaf, Y., Seegers, J., Spithoven, J.H., Buskens, E., van Baal, J.G., et al. Dutch iliac stent trial: long-term results in patients randomized for primary or selective stent placement. Radiology 238 (2006), 734–744.
Goode, S.D., Cleveland, T.J., Gaines, P.A., collaborators, St, Randomized clinical trial of stents versus angioplasty for the treatment of iliac artery occlusions (STAG trial). Br J Surg 100 (2013), 1148–1153.
Jongsma, H., Bekken, J., Ayez, N., Hoogewerf, C.J., Van Weel, V., Fioole, B., Angioplasty versus stenting for iliac artery lesions. Cochrane Database Syst Rev, 12, 2020, CD007561.
Krankenberg, H., Zeller, T., Ingwersen, M., Schmalstieg, J., Gissler, H.M., Nikol, S., et al. Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ICE trial. JACC Cardiovasc Interv 10 (2017), 1694–1704.
Mwipatayi, B.P., Sharma, S., Daneshmand, A., Thomas, S.D., Vijayan, V., Altaf, N., et al. Durability of the balloon-expandable covered versus bare-metal stents in the Covered versus Balloon Expandable Stent Trial (COBEST) for the treatment of aortoiliac occlusive disease. J Vasc Surg 64 (2016), 83–94 e1.
Bekken, J.A., Vroegindeweij, D., Vos, J.A., de Vries, J.P.M., Lardenoije, J., Petri, B.J., et al. Editor's Choice - Two year results of the randomised DISCOVER trial comparing covered versus bare metal stents in the common iliac artery. Eur J Vasc Endovasc Surg 65 (2023), 359–368.
Salem, M., Hosny, M.S., Francia, F., Sallam, M., Saratzis, A., Saha, P., et al. Management of extensive aorto-iliac disease: a systematic review and meta-analysis of 9319 patients. Cardiovasc Intervent Radiol 44 (2021), 1518–1535.
Premaratne, S., Newman, J., Hobbs, S., Garnham, A., Wall, M., Meta-analysis of direct surgical versus endovascular revascularization for aortoiliac occlusive disease. J Vasc Surg 72 (2020), 726–737.
Indes, J.E., Pfaff, M.J., Farrokhyar, F., Brown, H., Hashim, P., Cheung, K., et al. Clinical outcomes of 5358 patients undergoing direct open bypass or endovascular treatment for aortoiliac occlusive disease: a systematic review and meta-analysis. J Endovasc Ther 20 (2013), 443–455.
Starodubtsev, V., Mitrofanov, V., Ignatenko, P., Gostev, A., Preece, R., Rabtsun, A., et al. Editor's Choice - Hybrid vs. open surgical reconstruction for iliofemoral occlusive disease: a prospective randomised trial. Eur J Vasc Endovasc Surg 63 (2022), 557–565.
Capoccia, L., Riambau, V., da Rocha, M., Is femorofemoral crossover bypass an option in claudication?. Ann Vasc Surg 24 (2010), 828–832.
Eiberg, J.P., Roder, O., Stahl-Madsen, M., Eldrup, N., Qvarfordt, P., Laursen, A., et al. Fluoropolymer-coated dacron versus PTFE grafts for femorofemoral crossover bypass: randomised trial. Eur J Vasc Endovasc Surg 32 (2006), 431–438.
Ricco, J.B., Probst, H., French University Surgeons A. Long-term results of a multicenter randomized study on direct versus crossover bypass for unilateral iliac artery occlusive disease. J Vasc Surg 47 (2008), 45–53 discussion 53–4.
Changal, K.H., Syed, M.A., Dar, T., Mangi, M.A., Sheikh, M.A., Systematic review and proportional meta-analysis of endarterectomy and endovascular therapy with routine or selective stenting for common femoral artery atherosclerotic disease. J Interv Cardiol, 2019, 2019, 1593401.
Boufi, M., Ejargue, M., Gaye, M., Boyer, L., Alimi, Y., Loundou, A.D., Systematic review and meta-analysis of endovascular versus open repair for common femoral artery atherosclerosis treatment. J Vasc Surg 73 (2021), 1445–1455.
Ballotta, E., Gruppo, M., Mazzalai, F., Martella, B., Terranova, O., Da Giau, G., Infrapopliteal arterial reconstructions for limb salvage in patients aged > or =80 years according to preoperative ambulatory function and residential status. Surgery 148 (2010), 119–128.
Djerf, H., Millinger, J., Falkenberg, M., Jivegard, L., Svensson, M., Nordanstig, J., Absence of long-term benefit of revascularization in patients with intermittent claudication: five-year results from the IRONIC randomized controlled trial. J Vasc Surg, 72, 2020 747-47.
Gunnarsson, T., Gottsater, A., Bergman, S., Troeng, T., Lindgren, H., Eight-year outcome after invasive treatment of infrainguinal intermittent claudication: a population-based analysis from the Swedish vascular register (Swedvasc). SAGE Open Med, 8, 2020, 2050312120926782.
Howard, R., Albright, J., Fleckenstein, R., Forrest, A., Osborne, N., Corriere, M.A., et al. Identifying potentially avoidable femoral to popliteal expanded polytetrafluoroethylene bypass for claudication using cross-site blinded peer review. J Vasc Surg 77 (2023), 490–496 e8.
Baumgartner, I., Norgren, L., Fowkes, F.G.R., Mulder, H., Patel, M.R., Berger, J.S., et al. Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID Trial. J Am Coll Cardiol 72 (2018), 1563–1572.
Tepe, G., Brodmann, M., Werner, M., Bachinsky, W., Holden, A., Zeller, T., et al. Intravascular lithotripsy for peripheral artery calcification: 30-day outcomes from the randomized disrupt PAD III Trial. JACC Cardiovasc Interv 14 (2021), 1352–1361.
Tepe, G., Brodmann, M., Bachinsky, W., Holden, A., Zeller, T., Mangalmurti, S., et al. Intravascular lithotripsy for peripheral artery calcification: mid-term outcomes from the randomized disrupt PAD III Trial. J Soc Cardiovasc Angiogr Interv, 1, 2022, 100341.
Nordanstig, J., James, S., Andersson, M., Andersson, M., Danielsson, P., Gillgren, P., et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N Engl J Med 383 (2020), 2538–2546.
Dinh, K., Limmer, A.M., Chen, A.Z.L., Thomas, S.D., Holden, A., Schneider, P.A., et al. Mortality rates after paclitaxel-coated device use in patients with occlusive femoropopliteal disease: an updated systematic review and meta-analysis of randomized controlled trials. J Endovasc Ther 28 (2021), 755–777.
Zhang, C., Yin, G., Safety of paclitaxel-coated devices in the femoropopliteal arteries: a systematic review and meta-analysis. PLoS One, 17, 2022, e0275888.
Sridharan, N.D., Boitet, A., Smith, K., Noorbakhsh, K., Avgerinos, E., Eslami, M.H., et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. J Vasc Surg 67 (2018), 343–352.
Katsanos, K., Geisler, B.P., Garner, A.M., Zayed, H., Cleveland, T., Pietzsch, J.B., Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open, 6, 2016, e011245.
Tosaka, A., Soga, Y., Iida, O., Ishihara, T., Hirano, K., Suzuki, K., et al. Classification and clinical impact of restenosis after femoropopliteal stenting. J Am Coll Cardiol 59 (2012), 16–23.
Dake, M.D., Ansel, G.M., Jaff, M.R., Ohki, T., Saxon, R.R., Smouse, H.B., et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 133 (2016), 1472–1483 discussion 1483.
Goueffic, Y., Sauguet, A., Desgranges, P., Feugier, P., Rosset, E., Ducasse, E., et al. A polymer-free paclitaxel-eluting stent versus a bare-metal stent for de novo femoropopliteal lesions: the BATTLE Trial. JACC Cardiovasc Interv 13 (2020), 447–457.
Goueffic, Y., Torsello, G., Zeller, T., Esposito, G., Vermassen, F., Hausegger, K.A., et al. Efficacy of a drug-eluting stent versus bare metal stents for symptomatic femoropopliteal peripheral artery disease: primary results of the EMINENT randomized trial. Circulation 146 (2022), 1564–1576.
Bausback, Y., Wittig, T., Schmidt, A., Zeller, T., Bosiers, M., Peeters, P., et al. Drug-eluting stent versus drug-coated balloon revascularization in patients with femoropopliteal arterial disease. J Am Coll Cardiol 73 (2019), 667–679.
Liistro, F., Angioli, P., Porto, I., Ducci, K., Falsini, G., Ventoruzzo, G., et al. Drug-eluting balloon versus drug-eluting stent for complex femoropopliteal arterial lesions: the DRASTICO Study. J Am Coll Cardiol 74 (2019), 205–215.
Vroegindeweij, D., Kemper, F.J., Tielbeek, A.V., Buth, J., Landman, G., Recurrence of stenoses following balloon angioplasty and Simpson atherectomy of the femoro-popliteal segment. A randomised comparative 1-year follow-up study using colour flow duplex. Eur J Vasc Surg 6 (1992), 164–171.
Tielbeek, A.V., Vroegindeweij, D., Buth, J., Landman, G.H., Comparison of balloon angioplasty and Simpson atherectomy for lesions in the femoropopliteal artery: angiographic and clinical results of a prospective randomized trial. J Vasc Interv Radiol 7 (1996), 837–844.
Shammas, N.W., Coiner, D., Shammas, G.A., Dippel, E.J., Christensen, L., Jerin, M., Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. J Vasc Interv Radiol 22 (2011), 1223–1228.
Dattilo, R., Himmelstein, S.I., Cuff, R.F., The COMPLIANCE 360 degrees Trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol 26 (2014), 355–360.
Ott, I., Cassese, S., Groha, P., Steppich, B., Hadamitzky, M., Ibrahim, T., et al. Randomized comparison of paclitaxel-eluting balloon and stenting versus plain balloon plus stenting versus directional atherectomy for femoral artery disease (ISAR-STATH). Circulation 135 (2017), 2218–2226.
Zeller, T., Langhoff, R., Rocha-Singh, K.J., Jaff, M.R., Blessing, E., Amann-Vesti, B., et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR Study. Circ Cardiovasc Interv, 10, 2017, e004848.
Cai, Z., Guo, L., Qi, L., Cui, S., Tong, Z., Guo, J., et al. Midterm outcome of directional atherectomy combined with drug-coated balloon angioplasty versus drug-coated balloon angioplasty alone for femoropopliteal arteriosclerosis obliterans. Ann Vasc Surg 64 (2020), 181–187.
Saxon, R.R., Dake, M.D., Volgelzang, R.L., Katzen, B.T., Becker, G.J., Randomized, multicenter study comparing expanded polytetrafluoroethylene-covered endoprosthesis placement with percutaneous transluminal angioplasty in the treatment of superficial femoral artery occlusive disease. J Vasc Interv Radiol 19 (2008), 823–832.
Geraghty, P.J., Mewissen, M.W., Jaff, M.R., Ansel, G.M., VIBRANT Investigators. Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg 58 (2013), 386–395 e4.
Lammer, J., Zeller, T., Hausegger, K.A., Schaefer, P.J., Gschwendtner, M., Mueller-Huelsbeck, S., et al. Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol 38 (2015), 25–32.
Ambler, G.K., Twine, C.P., Graft type for femoro-popliteal bypass surgery. Cochrane Database Syst Rev, 2, 2018, CD001487.
Vossen, R.J., Fokkema, T.M., Vahl, A.C., Balm, R., Systematic review and meta-analysis comparing the autogenous vein bypass versus a prosthetic graft for above-the-knee femoropopliteal bypass surgery in patients with intermittent claudication. Vascular, 2022, 17085381221124701.
Sharrock, M., Antoniou, S.A., Antoniou, G.A., Vein versus prosthetic graft for femoropopliteal bypass above the knee: a systematic review and meta-analysis of randomized controlled trials. Angiology 70 (2019), 649–661.
Kim, Y., Thangappan, K., DeCarlo, C.S., Jessula, S., Majumdar, M., Patel, S.S., et al. Outcomes of femoropopliteal bypass for lifestyle-limiting claudication in the endovascular era. J Surg Res 279 (2022), 323–329.
Bosiers, M., Setacci, C., De Donato, G., Torsello, G., Silveira, P.G., Deloose, K., et al. ZILVERPASS Study: ZILVER PTX stent vs bypass surgery in femoropopliteal lesions. J Endovasc Ther 27 (2020), 287–295.
Zeller, T., Beschorner, U., Pilger, E., Bosiers, M., Deloose, K., Peeters, P., et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (BIOTRONIK'S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv 8 (2015), 1614–1622.
Rastan, A., Brechtel, K., Krankenberg, H., Zahorsky, R., Tepe, G., Noory, E., et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol 60 (2012), 587–591.
Levin, S.R., Farber, A., Osborne, N.H., Beck, A.W., McFarland, G.E., Rybin, D., et al. Tibial bypass in patients with intermittent claudication is associated with poor outcomes. J Vasc Surg 73 (2021), 564–571.e1.
Kobayashi, T., Hamamoto, M., Okazaki, T., Honma, T., Takahashi, S., Long-term results of distal bypass for intermittent claudication. Vasc Endovascular Surg 55 (2021), 5–10.
Qureshi, M.I., Li, H.L., Ambler, G.K., Wong, K.H.F., Dawson, S., Chaplin, K., et al. Antiplatelet and anticoagulant use in randomised trials of patients undergoing endovascular intervention for peripheral arterial disease: systematic review and narrative synthesis. Eur J Vasc Endovasc Surg 60 (2020), 77–87.
Katsanos, K., Spiliopoulos, S., Saha, P., Diamantopoulos, A., Karunanithy, N., Krokidis, M., et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One, 10, 2015, e0135692.
Tepe, G., Bantleon, R., Brechtel, K., Schmehl, J., Zeller, T., Claussen, C.D., et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy–the MIRROR study: a randomised and double-blinded clinical trial. Eur Radiol 22 (2012), 1998–2006.
Strobl, F.F., Brechtel, K., Schmehl, J., Zeller, T., Reiser, M.F., Claussen, C.D., et al. Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease. J Endovasc Ther 20 (2013), 699–706.
Hiatt, W.R., Bonaca, M.P., Patel, M.R., Nehler, M.R., Debus, E.S., Anand, S.S., et al. Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety. Circulation 142 (2020), 2219–2230.
Megaly, M., Abraham, B., Saad, M., Mekaiel, A., Soukas, P., Banerjee, S., et al. Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vasc Med 24 (2019), 313–323.
Hiatt, W.R., Money, S.R., Brass, E.P., Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 47 (2008), 330–336.
Bonaca, M.P., Bauersachs, R.M., Anand, S.S., Debus, E.S., Nehler, M.R., Patel, M.R., et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 382 (2020), 1994–2004.
Debus, E.S., Nehler, M.R., Govsyeyev, N., Bauersachs, R.M., Anand, S.S., Patel, M.R., et al. Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD Trial. Circulation 144 (2021), 1104–1116.
Krantz, M., Hiatt, W., Anand, S., Debus, E.S., Patel, M., Nehler, M., et al. Efficacy and safety of rivaroxaban in elderly patients with symptomatic PAD undergoing revascularization: insights from VOYAGER PAD. J Am Coll Cardiol, 77, 2021, 1783.
Morrison, J., Hiatt, W., Patel, M., Anand, S., Debus, E.S., Nehler, M., et al. Efficacy and safety of low-dose rivaroxaban in symptomatic PAD patients undergoing revascularization currently smoking: insights from VOYAGER PAD. J Am Coll Cardiol, 77, 2021, 1808.
Hsia, J., Nehler, M.R., Anand, S., Patel, M.R., Hiatt, W.R., Debus, S., et al. Rivaroxaban reduces major cardiovascular and limb events in patients with CKD and peripheral artery disease with recent lower extremity revascularization: insights from VOYAGER PAD. J Am Soc Nephrol, 31, 2020, 649.
Bauersachs, R.M., Szarek, M., Brodmann, M., Gudz, I., Debus, E.S., Nehler, M.R., et al. Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol 78 (2021), 317–326.
Hess, C.N., Anand, S., Bauersachs, R., Patel, M.R., Debus, E.S., Nehler, M.R., et al. Reduction in venous thromboembolism with rivaroxaban versus placebo in peripheral artery disease after lower extremity revascularization: insights from VOYAGER PAD. Circulation, 2020, 142.
Moll, F., Baumgartner, I., Jaff, M., Nwachuku, C., Tangelder, M., Ansel, G., et al. Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD Trial. J Endovasc Ther 25 (2018), 158–168.
Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial. Lancet 355 (2000), 346–351.
Tangelder, M.J., Algra, A., Lawson, J.A., Hennekes, S., Eikelboom, B.C., Optimal oral anticoagulant intensity to prevent secondary ischemic and hemorrhagic events in patients after infrainguinal bypass graft surgery. Dutch BOA Study Group. J Vasc Surg 33 (2001), 522–527.
Johnson, W.C., Williford, W.O., Department of Veterans Affairs Cooperative Study #362. Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study. J Vasc Surg 35 (2002), 413–421.
Belch, J.J., Dormandy, J., CASPAR Writing Committee, Biasi, G.M., Cairols, M., Diehm, C., et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg 52 (2010), 825–833.
Bedenis, R., Lethaby, A., Maxwell, H., Acosta, S., Prins, M.H., Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery. Cochrane Database Syst Rev, 2015, 2015, CD000535.
Bonaca, M.P., Bauersachs, R.M., Anand, S.S., Debus, E.S., Nehler, M.R., Patel, M.R., et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med 382 (2020), 1994–2004.
Govsyeyev, N., Nehler, M.R., Debus, S., Bauersachs, R., Patel, M., Anand, S., et al. Efficacy of rivaroxaban and aspirin in patients with peripheral artery disease with venous and prosthetic surgical bypass conduits: insights from the VOYAGER PAD Trial. J Vasc Surg 74 (2021), e24–e25.
Bonaca, M.P., Szarek, M., Debus, E.S., Nehler, M.R., Patel, M.R., Anand, S.S., et al. Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: a post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD. Clin Cardiol 45 (2022), 1143–1146.
Geraghty, A.J., Welch, K., Antithrombotic agents for preventing thrombosis after infrainguinal arterial bypass surgery. Cochrane Database Syst Rev, 2011, 2011, CD000536.
Monaco, M., Di Tommaso, L., Pinna, G.B., Lillo, S., Schiavone, V., Stassano, P., Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients. J Vasc Surg 56 (2012), 96–105.
van Hattum, E.S., Algra, A., Lawson, J.A., Eikelboom, B.C., Moll, F.L., Tangelder, M.J., Bleeding increases the risk of ischemic events in patients with peripheral arterial disease. Circulation 120 (2009), 1569–1576.
Lassila, R., Lepantalo, M., Lindfors, O., The effect of acetylsalicylic acid on the outcome after lower limb arterial surgery with special reference to cigarette smoking. World J Surg 15 (1991), 378–382.
McCollum, C., Alexander, C., Kenchington, G., Franks, P.J., Greenhalgh, R., Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial. J Vasc Surg 13 (1991), 150–161 discussion 161–2.
Clyne, C.A., Archer, T.J., Atuhaire, L.K., Chant, A.D., Webster, J.H., Random control trial of a short course of aspirin and dipyridamole (Persantin) for femorodistal grafts. Br J Surg 74 (1987), 246–248.
Shalaeva, E.V., Saner, H., Janabaev, B.B., Shalaeva, A.V., Tenfold risk increase of major cardiovascular events after high limb amputation with non-compliance for secondary prevention measures. Eur J Prev Cardiol 24 (2017), 708–716.
Sigvant, B., Kragsterman, B., Falkenberg, M., Hasvold, P., Johansson, S., Thuresson, M., et al. Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization. J Vasc Surg 64 (2016), 1009–10017 e3.
Cugusi, L., Manca, A., Yeo, T.J., Bassareo, P.P., Mercuro, G., Kaski, J.C., Nordic walking for individuals with cardiovascular disease: A systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 24 (2017), 1938–1955.
Armstrong, E.J., Chen, D.C., Westin, G.G., Singh, S., McCoach, C.E., Bang, H., et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc, 3, 2014, e000697.
Hobaus, C., Herz, C.T., Obendorf, F., Howanietz, M.T., Wrba, T., Koppensteiner, R., et al. Center-based patient care enhances survival of elderly patients suffering from peripheral arterial disease. Ann Med 49 (2017), 291–298.
Hussain, M.A., Al-Omran, M., Mamdani, M., Eisenberg, N., Premji, A., Saldanha, L., et al. Efficacy of a guideline-recommended risk-reduction program to improve cardiovascular and limb outcomes in patients with peripheral arterial disease. JAMA Surg 151 (2016), 742–750.
Aboyans, V., Ricco, J.B., Bartelink, M.L., Bjorck, M., Brodmann, M., Cohner, T., et al. [2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)]. Kardiol Pol 75 (2017), 1065–1160.
Gerhard-Herman, M.D., Gornik, H.L., Barrett, C., Barshes, N.R., Corriere, M.A., Drachman, D.E., et al. 2016 AHA/ACC Guideline on the Management of Patients with Lower Extremity Peripheral Artery Disease: Executive Summary. Vasc Med 22 (2017), NP1–NP43.
Venermo, M., Sprynger, M., Desormais, I., Bjorck, M., Brodmann, M., Cohnert, T., et al. Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society for Vascular Surgery. Eur J Prev Cardiol 26 (2019), 1971–1984.
Mills, J.L., Mechanisms of vein graft failure: the location, distribution, and characteristics of lesions that predispose to graft failure. Semin Vasc Surg 6 (1993), 78–91.
Shah, D.M., Darling, R.C. 3rd, Chang, B.B., Fitzgerald, K.M., Paty, P.S., Leather, R.P., Long-term results of in situ saphenous vein bypass. Analysis of 2058 cases. Ann Surg 222 (1995), 438–446 discussion 446–8.
Disselhoff, B., Buth, J., Jakimowicz, J., Early detection of stenosis of femoro-distal grafts. A surveillance study using colour-duplex scanning. Eur J Vasc Surg 3 (1989), 43–48.
Ihlberg, L., Luther, M., Alback, A., Kantonen, I., Lepantalo, M., Does a completely accomplished duplex-based surveillance prevent vein-graft failure?. Eur J Vasc Endovasc Surg 18 (1999), 395–400.
Griffin, N.M., Wright, I.A., Buckenham, T.M., Comparison of duplex ultrasound with digital subtraction angiography in the assessment of infra-inguinal autologous vein bypass grafts. ANZ J Surg 76 (2006), 966–969.
Mills, J.L., Bandyk, D.F., Gahtan, V., Esses, G.E., The origin of infrainguinal vein graft stenosis: a prospective study based on duplex surveillance. J Vasc Surg 21 (1995), 16–22 discussion 22–5.
Wixon, C.L., Mills, J.L., Westerband, A., Hughes, J.D., Ihnat, D.M., An economic appraisal of lower extremity bypass graft maintenance. J Vasc Surg 32 (2000), 1–12.
Bui, T.D., Mills, J.L. Sr, Ihnat, D.M., Gruessner, A.C., Goshima, K.R., Hughes, J.D., The natural history of duplex-detected stenosis after femoropopliteal endovascular therapy suggests questionable clinical utility of routine duplex surveillance. J Vasc Surg 55 (2012), 346–352.
Tielbeek, A.V., Rietjens, E., Buth, J., Vroegindeweij, D., Schol, F.P., The value of duplex surveillance after endovascular intervention for femoropopliteal obstructive disease. Eur J Vasc Endovasc Surg 12 (1996), 145–150.
Wong, K.H.F., Zucker, B.E., Wardle, B.G., Coughlin, P.A., Chaplin, K., Cheng, H.Y., et al. Systematic review and narrative synthesis of surveillance practices after endovascular intervention for lower limb peripheral arterial disease. J Vasc Surg 75 (2022), 372–80 e15.
Kornowski, R., Patient-reported outcome measures in cardiovascular disease. Eur Heart J Qual Care Clin Outcomes 9 (2023), 119–127.
Donker, J., de Vries, J., Ho, G.H., Goncalves, F.B., Hoeks, S.E., Verhagen, H.J., et al. Review: Quality of life in lower limb peripheral vascular surgery. Vascular 24 (2016), 88–95.
Guidon, M., McGee, H., Exercise-based interventions and health-related quality of life in intermittent claudication: a 20-year (1989–2008) review. Eur J Cardiovasc Prev Rehabil 17 (2010), 140–154.
Peri-Okonny, P.A., Wang, J., Gosch, K.L., Patel, M.R., Shishehbor, M.H., Safley, D.L., et al. Establishing thresholds for minimal clinically important differences for the Peripheral Artery Disease Questionnaire. Circ Cardiovasc Qual Outcomes, 14, 2021, e007232.
Gardner, A.W., Montgomery, P.S., Wang, M., Minimal clinically important differences in treadmill, 6-minute walk, and patient-based outcomes following supervised and home-based exercise in peripheral artery disease. Vasc Med 23 (2018), 349–357.
Conijn, A.P., Jonkers, W., Rouwet, E.V., Vahl, A.C., Reekers, J.A., Koelemay, M.J., Introducing the concept of the minimally important difference to determine a clinically relevant change on patient-reported outcome measures in patients with intermittent claudication. Cardiovasc Intervent Radiol 38 (2015), 1112–1118.
Nordanstig, J., Pettersson, M., Morgan, M., Falkenberg, M., Kumlien, C., Assessment of minimum important difference and substantial clinical benefit with the Vascular Quality of Life Questionnaire-6 when evaluating revascularisation procedures in peripheral arterial disease. Eur J Vasc Endovasc Surg 54 (2017), 340–347.
Cassar, K., Bachoo, P., Brittenden, J., The effect of peripheral percutaneous transluminal angioplasty on quality of life in patients with intermittent claudication. Eur J Vasc Endovasc Surg 26 (2003), 130–136.
Qvist, I., Lindholt, J.S., Sogaard, R., Lorentzen, V., Hallas, J., Frost, L., Randomised trial of telephone counselling to improve participants' adherence to prescribed drugs in a vascular screening trial. Basic Clin Pharmacol Toxicol 127 (2020), 477–487.
Flodgren, G., Rachas, A., Farmer, A.J., Inzitari, M., Shepperd, S., Interactive telemedicine: effects on professional practice and health care outcomes. Cochrane Database Syst Rev, 2015, 2015, CD002098.
Gandapur, Y., Kianoush, S., Kelli, H.M., Misra, S., Urrea, B., Blaha, M.J., et al. The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes 2 (2016), 237–244.
Medina, D., Zil, E.A.A., Daoud, D., Brooke, J., Lee Chester-Paul, K., Aziz, F., Implementation of transitional care planning is associated with reduced readmission rates in patients undergoing lower extremity bypass surgery for peripheral arterial disease. Ann Vasc Surg 84 (2022), 28–39.
Safran Naimark, J., Madar, Z., Shahar, D.R., The impact of a web-based app (eBalance) in promoting healthy lifestyles: randomized controlled trial. J Med Internet Res, 17, 2015, e56.
Michaud, T.L., Ern, J., Scoggins, D., Su, D., Assessing the impact of telemonitoring-facilitated lifestyle modifications on diabetes outcomes: a systematic review and meta-analysis. Telemed J E Health 27 (2021), 124–136.
Carter, T., O'Neill, S., Johns, N., Brady, R.R., Contemporary vascular smartphone medical applications. Ann Vasc Surg 27 (2013), 804–809.
Alushi, K., Hinterseher, I., Peters, F., Rother, U., Bischoff, M.S., Mylonas, S., et al. Distribution of mobile health applications amongst patients with symptomatic peripheral arterial disease in Germany: a cross-sectional survey study. J Clin Med, 11, 2022.
Donabedian, A., Evaluating the quality of medical care. Milbank Mem Fund Q 44:Suppl (1966), 166–206.
Hischke, S., Riess, H.C., Bublitz, M.K., Kriston, L., Schwaneberg, T., Harter, M., et al. Quality indicators in peripheral arterial occlusive disease treatment: a systematic review. Eur J Vasc Endovasc Surg 58 (2019), 738–745.
Bellmunt, S., Roque, M., Osorio, D., Pardo, H., Escudero, J.R., Bonfill, X., Healthcare quality indicators of peripheral artery disease based on systematic reviews. Eur J Vasc Endovasc Surg 48 (2014), 60–69.
Olin, J.W., Allie, D.E., Belkin, M., Bonow, R.O., Casey, D.E. Jr., Creager, M.A., et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). J Am Coll Cardiol 56 (2010), 2147–2181.
Riess, H.C., Debus, E.S., Schwaneberg, T., Hischke, S., Maier, J., Bublitz, M., et al. Indicators of outcome quality in peripheral arterial disease revascularisations - a Delphi expert consensus. Vasa 47 (2018), 491–497.
Vyas, M.V., Mrkobrada, M., Donner, A., Hackam, D.G., Underrepresentation of peripheral artery disease in modern cardiovascular trials: systematic review and meta-analysis. Int J Cardiol 168 (2013), 4875–4876.
Jelani, Q.U., Petrov, M., Martinez, S.C., Holmvang, L., Al-Shaibi, K., Alasnag, M., Peripheral arterial disease in women: an overview of risk factor profile, clinical features, and outcomes. Curr Atheroscler Rep, 20, 2018, 40.
Mayor, J.M., Preventza, O., McGinigle, K., Mills, J.L., Sr., Montero-Baker, M., Gilani, R., et al. Persistent under-representation of female patients in United States trials of common vascular diseases from 2008 to 2020. J Vasc Surg 75 (2022), 30–36.
Higgins, J.P., Higgins, J.A., Epidemiology of peripheral arterial disease in women. J Epidemiol 13 (2003), 1–14.
Vavra, A.K., Kibbe, M.R., Women and peripheral arterial disease. Womens Health (Lond) 5 (2009), 669–683.
Srivaratharajah, K., Abramson, B.L., Women and peripheral arterial disease: a review of sex differences in epidemiology, clinical manifestations, and outcomes. Can J Cardiol 34 (2018), 356–361.
Porras, C.P., Teraa, M., Bots, M.L., de Boer, A.R., Peters, S.A.E., van Doorn, S., et al. The frequency of primary healthcare contacts preceding the diagnosis of lower-extremity arterial disease: do women consult general practice differently?. J Clin Med, 11, 2022, 24.
Hirsch, A.T., Allison, M.A., Gomes, A.S., Corriere, M.A., Duval, S., Ershow, A.G., et al. A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation 125 (2012), 1449–1472.
Gardner, A.W., Sex differences in claudication pain in subjects with peripheral arterial disease. Med Sci Sports Exerc 34 (2002), 1695–1698.
Gardner, A.W., Parker, D.E., Montgomery, P.S., Khurana, A., Ritti-Dias, R.M., Blevins, S.M., Gender differences in daily ambulatory activity patterns in patients with intermittent claudication. J Vasc Surg 52 (2010), 1204–1210.
Wang, J.C., Criqui, M.H., Denenberg, J.O., McDermott, M.M., Golomb, B.A., Fronek, A., Exertional leg pain in patients with and without peripheral arterial disease. Circulation 112 (2005), 3501–3508.
Singh, N., Liu, K., Tian, L., Criqui, M.H., Guralnik, J.M., Ferrucci, L., et al. Leg strength predicts mortality in men but not in women with peripheral arterial disease. J Vasc Surg 52 (2010), 624–631.
Egorova, N., Vouyouka, A.G., Quin, J., Guillerme, S., Moskowitz, A., Marin, M., et al. Analysis of gender-related differences in lower extremity peripheral arterial disease. J Vasc Surg 51 (2010), 372–378 e1 discussion 378–9.
Freisinger, E., Malyar, N.M., Reinecke, H., Unrath, M., Low rate of revascularization procedures and poor prognosis particularly in male patients with peripheral artery disease - a propensity score matched analysis. Int J Cardiol 255 (2018), 188–194.
Behrendt, C.A., Sigvant, B., Kuchenbecker, J., Grima, M.J., Schermerhorn, M., Thomson, I.A., et al. Editor's Choice - International variations and sex disparities in the treatment of peripheral arterial occlusive disease: a report from VASCUNET and the International Consortium of Vascular Registries. Eur J Vasc Endovasc Surg 60 (2020), 873–880.
Lee, M.H., Li, P.Y., Li, B., Shakespeare, A., Samarasinghe, Y., Feridooni, T., et al. A systematic review and meta-analysis of sex- and gender-based differences in presentation severity and outcomes in adults undergoing major vascular surgery. J Vasc Surg 76 (2022), 581–94 e25.
Correia, R., Catarino, J., Vieira, I., Bento, R., Garcia, R., Pais, F., et al. Gender differences in chronic lower limb ischemia presentation and revascularization outcomes. Angiologia e Cirurgia Vascular 17 (2021), 110–116.
Parvar, S.L., Thiyagarajah, A., Nerlekar, N., King, P., Nicholls, S.J., A systematic review and meta-analysis of gender differences in long-term mortality and cardiovascular events in peripheral artery disease. J Vasc Surg 73 (2021), 1456–14565 e7.
Wang, J., He, Y., Shu, C., Zhao, J., Dubois, L., The effect of gender on outcomes after lower extremity revascularization. J Vasc Surg 65 (2017), 889–906 e4.
Altin, S.E., Gitto, M., Secemsky, E.A., Rao, S.V., Hess, C.N., Sex-based differences in periprocedural complications following lower extremity peripheral vascular intervention. Circ Cardiovasc Interv, 15, 2022, e011768.
Haine, A., Kavanagh, S., Berger, J.S., Hess, C.N., Norgren, L., Fowkes, F.G.R., et al. Sex-specific risks of major cardiovascular and limb events in patients with symptomatic peripheral artery disease. J Am Coll Cardiol 75 (2020), 608–617.
Rossouw, J.E., Anderson, G.L., Prentice, R.L., LaCroix, A.Z., Kooperberg, C., Stefanick, M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002), 321–333.
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288 (2002), 49–57.
Rossouw, J.E., Prentice, R.L., Manson, J.E., Wu, L., Barad, D., Barnabei, V.M., et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297 (2007), 1465–1477.
Simmons, A., Steffen, K., Peripheral arterial disease in women. Rev Cardiovasc Med 12 (2011), 123–131.
Schramm, K., Rochon, P.J., Gender differences in peripheral vascular disease. Semin Intervent Radiol 35 (2018), 9–16.
World Health Organization. Regional Office for Europe. Through a gender lens: women and tobacco in the WHO European Region. World Health Organization. Regional Office for Europe. 2021 https://apps.who.int/iris/handle/10665/339328.
Gabel, J., Jabo, B., Patel, S., Kiang, S., Bianchi, C., Chiriano, J., et al. Smoking habits of patients undergoing treatment for intermittent claudication in the Vascular Quality Initiative. Ann Vasc Surg 44 (2017), 261–268.
Bolego, C., Poli, A., Paoletti, R., Smoking and gender. Cardiovasc Res 53 (2002), 568–576.
McDermott, M.M., Greenland, P., Reed, G., Mazor, K.M., Merriam, P.A., Graff, R., et al. Gender differences in cholesterol-lowering medication prescribing in peripheral artery disease. Vasc Med 16 (2011), 428–435.
Peters, F., Kreutzburg, T., Riess, H.C., Heidemann, F., Marschall, U., L'Hoest, H., et al. Editor's Choice - Optimal pharmacological treatment of symptomatic peripheral arterial occlusive disease and evidence of female patient disadvantage: an analysis of health insurance claims data. Eur J Vasc Endovasc Surg 60 (2020), 421–429.
Campesi, I., Franconi, F., Seghieri, G., Meloni, M., Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes. Pharmacol Res 119 (2017), 195–207.
Alfredsson, J., Green, J.B., Stevens, S.R., Reed, S.D., Armstrong, P.W., Angelyn Bethel, M., et al. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: a report from TECOS. Diabetes Obes Metab 20 (2018), 2379–2388.
Mayor, J., Preventza, O., Mills, J.L., Montero-Baker, M., Gilani, R., Pallister, Z., et al. Persistent underrepresentation of female patients in US trials of common vascular diseases since 2008. J Vasc Surg, 73, 2021, e23.
Jain, R.K., Laiteerapong, N., Strategies for improving cardiovascular health in women with diabetes mellitus: a review of the evidence. Curr Diab Rep, 15, 2015, 98.
Makowski, L., Feld, J., Koppe, J., Illner, J., Kuhnemund, L., Wiederhold, A., et al. Sex related differences in therapy and outcome of patients with intermittent claudication in a real-world cohort. Atherosclerosis 325 (2021), 75–82.
Ramkumar, N., Suckow, B.D., Brown, J.R., Sedrakyan, A., Cronenwett, J.L., Goodney, P.P., Sex-based assessment of patient presentation, lesion characteristics, and treatment modalities in patients undergoing peripheral vascular intervention. Circ Cardiovasc Interv, 11, 2018, e005749.
Messiha, D., Petrikhovich, O., Lortz, J., Mahabadi, A.A., Hering, R., Schulz, M., et al. Gender differences in outpatient peripheral artery disease management in Germany: a population based study 2009–2018. Eur J Vasc Endovasc Surg 63 (2022), 714–720.
Pande, R.L., Creager, M.A., Socioeconomic inequality and peripheral artery disease prevalence in US adults. Circ Cardiovasc Qual Outcomes 7 (2014), 532–539.
Rudolf, H., Kreutzer, J., Klaassen-Mielke, R., Timmesfeld, N., Trampisch, H.J., Krause, D.M.J., Socioeconomic factors and the onset of peripheral artery disease in older adults. Vasa 50 (2021), 341–347.
Vart, P., Coresh, J., Kwak, L., Ballew, S.H., Heiss, G., Matsushita, K., Socioeconomic status and incidence of hospitalization with lower-extremity peripheral artery disease: atherosclerosis risk in communities study. J Am Heart Assoc, 6, 2017, e004995.
Kroger, K., Dragano, N., Stang, A., Moebus, S., Mohlenkamp, S., Mann, K., et al. An unequal social distribution of peripheral arterial disease and the possible explanations: results from a population-based study. Vasc Med 14 (2009), 289–296.
Subherwal, S., Patel, M.R., Tang, F., Smolderen, K.G., Jones, W.S., Tsai, T.T., et al. Socioeconomic disparities in the use of cardioprotective medications among patients with peripheral artery disease: an analysis of the American College of Cardiology's NCDR PINNACLE Registry. J Am Coll Cardiol 62 (2013), 51–57.
Jin, J., Sklar, G.E., Min Sen Oh, V., Chuen Li, S., Factors affecting therapeutic compliance: a review from the patient's perspective. Ther Clin Risk Manag 4 (2008), 269–286.
Vitalis, A., Lip, G.Y., Kay, M., Vohra, R.K., Shantsila, A., Ethnic differences in the prevalence of peripheral arterial disease: a systematic review and meta-analysis. Expert Rev Cardiovasc Ther 15 (2017), 327–338.
Selvin, E., Erlinger, T.P., Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation 110 (2004), 738–743.
Allison, M.A., Criqui, M.H., McClelland, R.L., Scott, J.M., McDermott, M.M., Liu, K., et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 48 (2006), 1190–1197.
Sabatine, M.S., Blake, G.J., Drazner, M.H., Morrow, D.A., Scirica, B.M., Murphy, S.A., et al. Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatment. Circulation 111 (2005), 1217–1224.
Lurie, N., Fremont, A., Jain, A.K., Taylor, S.L., McLaughlin, R., Peterson, E., et al. Racial and ethnic disparities in care: the perspectives of cardiologists. Circulation 111 (2005), 1264–1269.
Hutchinson, R.G., Watson, R.L., Davis, C.E., Barnes, R., Brown, S., Romm, F., et al. Racial differences in risk factors for atherosclerosis. The ARIC Study. Atherosclerosis Risk in Communities. Angiology 48 (1997), 279–290.
Abbasi, F., Brown, B.W. Jr., Lamendola, C., McLaughlin, T., Reaven, G.M., Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 40 (2002), 937–943.
Jones, D.W., Chambless, L.E., Folsom, A.R., Heiss, G., Hutchinson, R.G., Sharrett, A.R., et al. Risk factors for coronary heart disease in African Americans: the atherosclerosis risk in communities study, 1987–1997. Arch Intern Med 162 (2002), 2565–2571.
Eslami, M.H., Zayaruzny, M., Fitzgerald, G.A., The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia. J Vasc Surg 45 (2007), 55–59.
Rowe, V.L., Weaver, F.A., Lane, J.S., Etzioni, D.A., Racial and ethnic differences in patterns of treatment for acute peripheral arterial disease in the United States, 1998–2006. J Vasc Surg 51 (2010), 21S–26S.
Hughes, K., Boyd, C., Oyetunji, T., Tran, D., Chang, D., Rose, D., et al. Racial/ethnic disparities in revascularization for limb salvage: an analysis of the National Surgical Quality Improvement Program database. Vasc Endovascular Surg 48 (2014), 402–405.
Strain, W.D., Paldanius, P.M., Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol, 17, 2018, 57.
Yang, S.L., Zhu, L.Y., Han, R., Sun, L.L., Li, J.X., Dou, J.T., Pathophysiology of peripheral arterial disease in diabetes mellitus. J Diabetes 9 (2017), 133–140.
Stalling, P., Engelbertz, C., Luders, F., Meyborg, M., Gebauer, K., Waltenberger, J., et al. Unmet medical needs in intermittent claudication with diabetes and coronary artery disease - a “real-world” analysis on 21 197 PAD patients. Clin Cardiol 42 (2019), 629–636.
Jensen, S.A., Vatten, L.J., Myhre, H.O., The association between diabetes mellitus and the prevalence of intermittent claudication: the HUNT study. Vasc Med 13 (2008), 239–244.
Hageman, D., Gommans, L.N., Scheltinga, M.R., Teijink, J.A., Effect of diabetes mellitus on walking distance parameters after supervised exercise therapy for intermittent claudication: a systematic review. Vasc Med 22 (2017), 21–27.
Stoberock, K., Kaschwich, M., Nicolay, S.S., Mahmoud, N., Heidemann, F., Riess, H.C., et al. The interrelationship between diabetes mellitus and peripheral arterial disease. Vasa 50 (2021), 323–330.
Dakhel, A., Zarrouk, M., Ekelund, J., Acosta, S., Nilsson, P., Miftaraj, M., et al. Worse cardiovascular prognosis after endovascular surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes. Ther Adv Endocrinol Metab, 11, 2020, 2042018820960294.
Adler, A.I., Stevens, R.J., Neil, A., Stratton, I.M., Boulton, A.J., Holman, R.R., UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 25 (2002), 894–899.
Vijan, S., Stevens, D.L., Herman, W.H., Funnell, M.M., Standiford, C.J., Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus. Putting evidence into practice. J Gen Intern Med 12 (1997), 567–580.
Dakhel, A., Zarrouk, M., Ekelund, J., Acosta, S., Miftaraj, M., Eliasson, B., et al. Higher long-term cardiovascular morbidity after open surgery for intermittent claudication caused by infrainguinal atherosclerotic disease in patients with diabetes - a nationwide observational cohort study. Vasa 50 (2021), 224–230.
Behrendt, C.A., Venermo, M., Cronenwett, J.L., Sedrakyan, A., Beck, A.W., Eldrup-Jorgensen, J., et al. VASCUNET, VQI, and the International Consortium of Vascular Registries - unique collaborations for quality improvement in vascular surgery. Eur J Vasc Endovasc Surg 58 (2019), 792–793.
Lees, T., Troeng, T., Thomson, I.A., Menyhei, G., Simo, G., Beiles, B., et al. International variations in infrainguinal bypass surgery - a VASCUNET report. Eur J Vasc Endovasc Surg 44 (2012), 185–192.
Behrendt, C.A., Sigvant, B., Szeberin, Z., Beiles, B., Eldrup, N., Thomson, I.A., et al. International variations in amputation practice: a VASCUNET report. Eur J Vasc Endovasc Surg 56 (2018), 391–399.
